text stringlengths 116 6.55k | conversation_id int64 77.2k 898k | embedding list | cluster int64 33 33 |
|---|---|---|---|
Please summerize the given abstract to a title
COVID-19 vaccines: Current evidence and considerations
The coronavirus disease 2019 (COVID-19) pandemic is a global crisis, with devastating health, business and social impacts. Vaccination is a safe, simple, and effective way of protecting a person against COVID-19. By the end of August 2021, only 24.6% of the world population has received two doses of a COVID-19 vaccine. Since the emergence of COVID-19, several COVID-19 vaccines have been developed and approved for emergency use. Current vaccines have shown efficacy with low risk of adverse effects. However, COVID-19 vaccines have been related to a relatively small number of cases of heart inflammation, anaphylaxis (allergic reactions), and blood clots formation. On the other hand, COVID-19 vaccination is not recommended for children less than 12 years of age. Furthermore, It has been proposed that some new variants (e.g., Lambda and Delta) are proficient in escaping from the antiviral immunity elicited by vaccination. Herein we present current considerations regarding the COVID-19 vaccines including: efficacy against new variants, challenges in distribution, disparities in availability, dosage gender and race difference, COVID-19 vaccine transport and storage, limitations in children and pregnant women. Long-time monitoring is essential in order to find vaccine efficacy and to rule out related side effects.
| 77,198 | [
0.20703125,
0.168701171875,
-0.5771484375,
0.63134765625,
-0.64501953125,
-0.02593994140625,
-0.54931640625,
0.52490234375,
0.313720703125,
0.2198486328125,
0.470947265625,
-0.51123046875,
-0.399169921875,
-0.352783203125,
-0.357666015625,
0.71728515625,
-0.73486328125,
-0.63769531... | 33 |
Please summerize the given abstract to a title
[Pharmacotherapeutic options for SARS-CoV-2 infection / COVID-19]
There is currently no proven effective therapy for COVID-19 Without wishing to be exhaustive, the drugs most studied in this regard are presented below Each of the listed therapeutic options is considered experimental at this stage However, given the severe public health implications of the epidemic and the potentially fatal outcome of COVID-19 patients treated in the intensive care unit, their use 'off-label' should be considered Orv Hetil 2020;161 (17): 685-688
| 77,248 | [
0.2841796875,
-0.4248046875,
-0.48291015625,
0.693359375,
-1.0341796875,
-0.62744140625,
-0.21240234375,
0.294677734375,
0.80712890625,
0.24267578125,
0.517578125,
-0.350830078125,
0.244140625,
-0.41748046875,
-0.0645751953125,
1.033203125,
-0.379638671875,
-0.61865234375,
-0.072... | 33 |
Please summerize the given abstract to a title
Hydroxychloroquine and chloroquine in COVID-19: should they be used as standard therapy?
The pandemic of the new coronavirus, known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has urged the nations to an unprecedented world-wide reaction, including an accelerated exploration of therapeutic options. In the absence of a vaccine and specifically designed antivirals, the medical community has proposed the use of various previously available medications in order to reduce the number of patients requiring prolonged hospitalizations, oxygen therapy, and mechanical ventilation and to decrease mortality from coronavirus disease 2019 (COVID-19). Hydroxychloroquine and chloroquine are among the proposed drugs and are the most widely used so far, despite the lack of robust evidence on their usefulness. The objective of this article is to review and discuss the possible role of these drugs in the therapy of COVID-19.
| 77,335 | [
0.7412109375,
-0.410888671875,
0.0277099609375,
0.67919921875,
-0.990234375,
-0.09088134765625,
-0.126708984375,
0.327880859375,
0.51904296875,
0.3095703125,
0.703125,
-0.468017578125,
-0.094970703125,
-0.71337890625,
-0.37109375,
0.33544921875,
-0.302734375,
-0.98681640625,
-0.0... | 33 |
Please summerize the given abstract to a title
A Veterinary Vaccine for SARS-CoV-2: The First COVID-19 Vaccine for Animals
As coronaviruses have a wide range of host species, many animals harbor these pathogens, however only a handful of them become severely infected [...].
| 77,365 | [
0.1441650390625,
-0.29931640625,
0.06329345703125,
0.10284423828125,
-0.41845703125,
-0.08782958984375,
-0.215087890625,
1.083984375,
0.421142578125,
0.28173828125,
0.048919677734375,
-0.2406005859375,
-0.05352783203125,
0.034332275390625,
-0.6123046875,
0.052703857421875,
-0.2271728... | 33 |
Please summerize the given abstract to a title
COVID-19: Vaccine Delivery System, Drug Repurposing and Application of Molecular Modeling Approach
The acute respiratory syndrome coronavirus (SARS-CoV-2) has spread across the world, resulting in a pandemic COVID-19 which is a human zoonotic disease that is caused by a novel coronavirus (CoV) strain thought to have originated in wild or captive bats in the initial COVID outbreak region. The global COVID-19 outbreak started in Guangdong Province, China’s southernmost province. The global response to the COVID-19 pandemic has been hampered by the sheer number of infected people, many of whom need intensive care before succumbing to the disease. The epidemic is being handled by a combination of disease control by public health interventions and compassionate treatment for those who have been impacted. There is no clear anti-COVID-19 medication available at this time. However, the need to find medications that can turn the tide has led to the development of a number of investigational drugs as potential candidates for improving outcomes, especially in the severely and critically ill. Although many of these adjunctive medications are still being studied in clinical trials, professional organizations have attempted to define the circumstances in which their use is deemed off-label or compassionate. It is important to remind readers that new information about COVID-19’s clinical features, treatment options, and outcomes is released on a regular basis. The mainstay of treatment remains optimized supportive care, and the therapeutic effectiveness of the subsequent agents is still being studied.
| 77,374 | [
0.04864501953125,
0.0204620361328125,
-0.4609375,
0.4091796875,
-0.5087890625,
-0.381591796875,
-0.50537109375,
0.218994140625,
0.455078125,
0.08245849609375,
0.5478515625,
-0.7373046875,
-0.442626953125,
-0.427490234375,
-0.60009765625,
0.09954833984375,
-0.6181640625,
-0.63427734... | 33 |
Please summerize the given abstract to a title
Therapy of Type 2 Diabetes in Patients with SARS-CoV-2 Infection
COVID-19 infection poses an important clinical therapeutic problem, especially in patients with coexistent diseases such as type 2 diabetes. Potential pathogenetic links between COVID-19 and diabetes include inflammation, effects on glucose homeostasis, haemoglobin deoxygenation, altered immune status and activation of the renin-angiotensin-aldosterone system (RAAS). Moreover, drugs often used in the clinical care of diabetes (dipeptidyl peptidase 4 inhibitors, glucagon-like peptide 1 receptor agonists, sodium-glucose cotransporter 2 inhibitors, metformin and insulin) may influence the course of SARS-CoV-2 infection, so it is very important to verify their effectiveness and safety. This review summarises the new advances in diabetes therapy and COVID-19 and provides clinical recommendations that are essential for medical doctors and for patients suffering from type 2 diabetes.
| 77,393 | [
0.3232421875,
0.205322265625,
0.0116729736328125,
0.6953125,
-0.61767578125,
-0.093994140625,
-0.436279296875,
0.307861328125,
0.12176513671875,
0.69775390625,
0.1715087890625,
-0.2490234375,
0.21826171875,
-0.77783203125,
-0.1888427734375,
0.437744140625,
-0.440185546875,
-0.36230... | 33 |
Please summerize the given abstract to a title
Systemic Medications of Dermatological Importance in COVID-19
Early December 2019 witnessed an international outbreak of a novel coronavirus (COVID 19) designated severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) Since then, a number of therapeutic molecules have been explored to have potential efficacy against the SARS-Cov-2 per se or its sequelae There are no Food and Drug Administration specific therapies approved so far;however, numerous drugs based on varying levels of evidence, in vitro studies and compassionate drug trials are being established as therapeutic agents, especially drugs approved for previous emergence of the severe acute respiratory syndrome (SARS-CoV-1) and Middle east respiratory syndrome coronavirus (MERS-Cov) Numerous active clinical trials for COVID-19 with more than 150 drugs and products are under study Needless to say, many dermatological drugs are being employed to mitigate this pandemic threat We aim to review drugs with potential against SARS-Cov-2 widely used in dermatology practice Additionally, rampant and overzealous use of these drugs as well as introduction of new molecules might lead to emergence of adverse effects associated with these agents Dermatologists must be on lookout for any cutaneous adverse effects of these drugs J Drugs Dermatol 2020;19(9):889-892 doi:10 36849/JDD 2020 5323
| 77,403 | [
0.340087890625,
-0.1478271484375,
-0.135986328125,
0.22412109375,
-0.96240234375,
-0.19140625,
-0.29345703125,
0.273681640625,
0.09442138671875,
0.5751953125,
0.393310546875,
-0.71875,
0.03875732421875,
-0.5390625,
-0.178955078125,
0.260498046875,
-0.1895751953125,
-0.2115478515625... | 33 |
Please summerize the given abstract to a title
Immunopathological Roles of Neutrophils in Virus Infection and COVID-19
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been spread around the world and is currently affecting global public health. Clinical evidence indicates that the elevated number of peripheral neutrophils and higher ratio of neutrophils-to-lymphocytes are correlated with severe outcomes in COVID-19 patients, suggesting the possible immunopathological role of neutrophils during SARS-CoV-2 infection. As an abundant innate immune cell type, neutrophils are well known for their contributions to antimicrobial defense. However, their dysfunction is also associated with different inflammatory signatures during the pathogenesis of infection. Herein, in this mini-review, we summarize the recent progress on the potential role of neutrophils during COVID-19-associated inflammatory responses. In particular, we highlight the interactions between neutrophils and viruses as well as the relationship of neutrophils with cytokine storm and thrombosis in COVID-19 patients. Lastly, we discuss the importance of neutrophils as potential therapeutic targets for COVID-19.
| 77,468 | [
0.03436279296875,
-0.160888671875,
-0.267578125,
0.86572265625,
-0.441650390625,
-0.1209716796875,
0.052398681640625,
0.35693359375,
0.07354736328125,
0.81689453125,
0.340087890625,
-0.31640625,
0.335205078125,
-0.5224609375,
-0.06689453125,
-0.12164306640625,
-0.1812744140625,
-0.... | 33 |
Please summerize the given abstract to a title
Contribution of Nanotechnology in the Fight Against COVID-19
Coronavirus disease (COVID-19) is a respiratory infectious disease caused by a newly discovered virus strain, severe acute respiratory syndrome coronavirus-2 (SARS-Cov-2) This pandemic spread quickly across nations with a high mortality rate in immunocompromised patients This contagious disease posed a serious threat to health systems It impacted the continents of the earth in a way that could not have been predicted Therefore, many leading funding agencies announced the call for proposal to diagnosis and treatment of COVID-19 pandemic using advanced technology-based methods, including nanotechnology The researchers coming from the nanotechnology community can contribute their efforts to cope with COVID-19 As a community member of nanotechnology, we suggest some new research targets that can be designed and improved, optimized, and developed the existing/new materials in the sub-field of diagnostics and healthcare of nanotechnology The potential research targets to fight against COVID-19 includes Point-of-care diagnostics (POCD), surveillance and monitoring, novel therapeutics, vaccine development, research, and development, repurposing existing drugs with potential therapeutic applications, development of antiviral nanocoating/antimicrobial spray-based coating for PPE, magnetic nanoparticles and viral RNA and rapid detection kits
| 77,544 | [
0.09381103515625,
0.0236053466796875,
-0.0870361328125,
0.3818359375,
-0.2242431640625,
-0.2105712890625,
-0.267822265625,
0.164306640625,
0.30029296875,
0.30224609375,
0.61669921875,
-0.64599609375,
0.296630859375,
-0.476318359375,
-0.485595703125,
0.1279296875,
-0.1241455078125,
... | 33 |
Please summerize the given abstract to a title
Antiviral Potential of Nanoparticles-Can Nanoparticles Fight Against Coronaviruses?
Infectious diseases account for more than 20% of global mortality and viruses are responsible for about one-third of these deaths. Highly infectious viral diseases such as severe acute respiratory (SARS), Middle East respiratory syndrome (MERS) and coronavirus disease (COVID-19) are emerging more frequently and their worldwide spread poses a serious threat to human health and the global economy. The current COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of 27 July 2020, SARS-CoV-2 has infected over 16 million people and led to the death of more than 652,434 individuals as on 27 July 2020 while also causing significant economic losses. To date, there are no vaccines or specific antiviral drugs to prevent or treat COVID-19. Hence, it is necessary to accelerate the development of antiviral drugs and vaccines to help mitigate this pandemic. Non-Conventional antiviral agents must also be considered and exploited. In this regard, nanoparticles can be used as antiviral agents for the treatment of various viral infections. The use of nanoparticles provides an interesting opportunity for the development of novel antiviral therapies with a low probability of developing drug resistance compared to conventional chemical-based antiviral therapies. In this review, we first discuss viral mechanisms of entry into host cells and then we detail the major and important types of nanomaterials that could be used as antiviral agents. These nanomaterials include silver, gold, quantum dots, organic nanoparticles, liposomes, dendrimers and polymers. Further, we consider antiviral mechanisms, the effects of nanoparticles on coronaviruses and therapeutic approaches of nanoparticles. Finally, we provide our perspective on the future of nanoparticles in the fight against viral infections.
| 77,684 | [
-0.01198577880859375,
-0.33056640625,
-0.0277099609375,
0.55029296875,
-0.6435546875,
0.026458740234375,
-0.80322265625,
0.37890625,
0.395751953125,
0.69189453125,
0.4501953125,
-0.42236328125,
0.265380859375,
-0.272216796875,
-0.493896484375,
0.497802734375,
-0.188720703125,
-1.05... | 33 |
Please summerize the given abstract to a title
Vitamin D, zinc and glutamine: Synergistic action with OncoTherad immunomodulator in interferon signaling and COVID19 (Review)
Coronavirus disease 2019 (COVID19), caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV2), was identified in December, 2019 in Wuhan, China. Since then, it has continued to spread rapidly in numerous countries, while the search for effective therapeutic options persists. Coronaviruses, including SARSCoV2, are known to suppress and evade the antiviral responses of the host organism mediated by interferon (IFN), a family of cytokines that plays an important role in antiviral defenses associated with innate immunity, and has been used therapeutically for chronic viral diseases and cancer. On the other hand, OncoTherad, a safe and effective immunotherapeutic agent in the treatment of nonmuscle invasive bladder cancer (NMIBC), increases IFN signaling and has been shown to be a promising therapeutic approach for COVID19 in a case report that described the rapid recovery of a 78yearold patient with NMIBC with comorbidities. The present review discusses the possible synergistic action of OncoTherad with vitamin D, zinc and glutamine, nutrients that have been shown to facilitate immune responses mediated by IFN signaling, as well as the potential of this combination as a therapeutic option for COVID19.
| 77,820 | [
-0.228515625,
-0.5322265625,
-0.03155517578125,
0.74072265625,
-0.64599609375,
-0.1385498046875,
-0.1171875,
0.235595703125,
0.48486328125,
0.45263671875,
0.259521484375,
-0.16015625,
0.056549072265625,
-0.461669921875,
-0.2286376953125,
-0.031951904296875,
-0.426025390625,
-0.6938... | 33 |
Please summerize the given abstract to a title
A review on Remdesivir: A broad-spectrum antiviral molecule for possible COVID-19 treatment.
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a novel coronavirus strain and the causative agent of COVID-19 was identified to have emerged in Wuhan, China, in December 2019 [1]. This pandemic situation and magnitude of suffering has led to global effort to find out effective measures for discovery of new specific drugs and vaccines to combat this deadly disease. In addition to many initiatives to develop vaccines for protective immunity against SARS-CoV-2, some of which are at various stages of clinical trials researchers worldwide are currently using available conventional therapeutic drugs with potential to combat the disease effectively in other viral infections and it is believed that these antiviral drugs could act as a promising immediate alternative. Remdesivir (RDV), a broad-spectrum anti-viral agent, initially developed for the treatment of Ebola virus (EBOV) and known to show promising efficiency in in vitro and in vivo studies against SARS and MERS coronaviruses, is now being investigated against SARS-CoV-2. On May 1, 2020, The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for RDV to treat COVID-19 patients [2]. A number of multicentre clinical trials are on-going to check the safety and efficacy of RDV for the treatment of COVID-19. Results of published double blind, and placebo-controlled trial on RDV against SARS-CoV-2, showed that RDV administration led to faster clinical improvement in severe COVID-19 patients compared to placebo. This review highlights the available knowledge about RDV as a therapeutic drug for coronaviruses and its preclinical and clinical trials against COVID-19.
| 77,825 | [
-0.0435791015625,
-0.311767578125,
-0.318115234375,
0.591796875,
-0.615234375,
0.1361083984375,
-0.3994140625,
0.330078125,
-0.12646484375,
0.7802734375,
0.4794921875,
-0.775390625,
0.26904296875,
-0.491943359375,
-0.26220703125,
0.038665771484375,
-0.5390625,
-0.56787109375,
-0.... | 33 |
Please summerize the given abstract to a title
Delivery Routes for COVID-19 Vaccines
The novel coronavirus, SARS-CoV-2, which causes COVID-19, has resulted in a pandemic with millions of deaths. To eradicate SARS-CoV-2 and prevent further infections, many vaccine candidates have been developed. These vaccines include not only traditional subunit vaccines and attenuated or inactivated viral vaccines but also nucleic acid and viral vector vaccines. In contrast to the diversity in the platform technology, the delivery of vaccines is limited to intramuscular vaccination. Although intramuscular vaccination is safe and effective, mucosal vaccination could improve the local immune responses that block the spread of pathogens. However, a lack of understanding of mucosal immunity combined with the urgent need for a COVID-19 vaccine has resulted in only intramuscular vaccinations. In this review, we summarize the history of vaccines, current progress in COVID-19 vaccine technology, and the status of intranasal COVID-19 vaccines. Future research should determine the most effective route for vaccine delivery based on the platform and determine the mechanisms that underlie the efficacy of different delivery routes.
| 78,053 | [
0.330322265625,
-0.120361328125,
-0.38916015625,
0.68701171875,
-0.501953125,
0.228759765625,
-0.472900390625,
0.77197265625,
0.126953125,
0.50537109375,
0.14306640625,
-0.222412109375,
0.079345703125,
-0.470947265625,
-0.498291015625,
0.3330078125,
-0.2496337890625,
-0.39916992187... | 33 |
Please summerize the given abstract to a title
Drug delivery systems as Immunomodulators for therapy of infectious disease: relevance to COVID-19
The emergence of SARS-CoV-2, and the ensuing global pandemic, has resulted in an unprecedented response to identify therapies that can limit uncontrolled inflammation observed in patients with moderate to severe COVID-19. The immune pathology behind COVID-19 is complex and involves the activation and interaction of multiple systems including, but not limited to, complement, inflammasomes, endothelial as well as innate and adaptive immune cells to bring about a convoluted profile of inflammation, coagulation and tissue damage. To date, therapeutic approaches have focussed on inhibition of coagulation, untargeted immune suppression and/or cytokine-directed blocking agents. Regardless of recently achieved improvements in individual patient outcomes and survival rates, improved and focussed approaches targeting individual systems involved is needed to further improve prognosis and wellbeing. This review summarizes the current understanding of molecular and cellular systems involved in the pathophysiology of COVID-19, and their contribution to pathogen clearance and damage to then discuss possible therapeutic options involving immunomodulatory drug delivery systems as well as summarising the complex interplay between them.
| 78,105 | [
0.22314453125,
-0.189453125,
-0.343017578125,
0.84765625,
-0.69921875,
-0.06524658203125,
-0.2427978515625,
-0.020843505859375,
0.09893798828125,
0.6162109375,
-0.20654296875,
0.07147216796875,
0.08038330078125,
-0.0284576416015625,
0.01053619384765625,
0.251953125,
-0.482666015625,
... | 33 |
Please summerize the given abstract to a title
Management of sars-cov-2 (Covid-19) infection with special focus on use of hydroxychloroquine and lopinavir/ritonavir
Editor’s comment-A The covid-19 pandemic is the greatest challenge for the current generation of physicians, scientists and health administrators B Strict use of PPE, face masks, isolation and quarantine are the most effective methods of prevention of this infection C The immunomodulator hydroxychloroquine is approved for prophylactic use in asymptomatic health care workers and household contacts It is also approved as compassionate use for treatment of active covid-19 cases in the USA D Lopinavir/ritonavir and remdesivir are used in some countries, but efficacy is doubtful E Treatment with convalescent plasma may be considered in emergency situations
| 78,131 | [
0.7626953125,
-0.037200927734375,
-0.5654296875,
0.65380859375,
-0.697265625,
0.30029296875,
-0.441650390625,
0.4521484375,
0.57177734375,
0.5400390625,
0.263427734375,
-0.34765625,
-0.0643310546875,
-0.07342529296875,
-0.409423828125,
0.34130859375,
-0.7177734375,
-0.908203125,
... | 33 |
Please summerize the given abstract to a title
[Umifenovir and coronavirus infections: a review of research results and clinical practice]
Coronaviruses are known to cause acute respiratory infections. Antiviral therapy, including for COVID-19, is based on clinical practice, experimental data and trial results. The purpose of this review is to: provide and systematize actual preclinical data, clinical trials results and clinical practice for antiviral agent umifenovir (Arbidol). Databases Scopus, Web of Science, RSCI and medRxiv were used for publication searching from 2004. A meta-analysis of clinical trials results was performed. Umifenovir is antiviral agent, it belongs to fusion inhibitors, interacts with SARS-CoV-2 spike protein. Umifenovir the impede the trimerization of spike glycoprotein and inhibit host cell adhesion, at the level of the coronaviruses S-protein of interaction with ACE2 receptor. Preclinical studies in vitro and on animals show umifenovir activity against a number of coronaviruses, including SARS-CoV, MERS-CoV, SARS-CoV-2, and others. Umifenovir, in combination with other antiviral drugs, symptomatic or traditional medicine, was used in China to treat patients with COVID-19, resulting in reduced mortality, virus elimination, the frequency of more severe course and complications in middle severity. However, antiviral therapy for the treatment of severe patients, with ARDS, did not lead to improved outcomes. In comparative clinical studies, umifenovir showed similar effectiveness with other antiviral drugs, and lower frequency of adverse reactions. Therapy with umifenovir, led to an increase percentage of patients with negative results of PCR tests on days 714 (I2=69.8%, RR 0.48, 95% CI 0.190.76; p=0.001). The efficacy and safety of antivirals against SARS-CoV-2 still requires clinical investigation. Moderate forms of COVID-19 could be effectively treated by antivirals, but severe forms of COVID-19, characterized by pulmonary immunopathology, require different approaches to treatment.
| 78,190 | [
-0.060333251953125,
-0.29833984375,
0.4208984375,
0.2125244140625,
-0.45751953125,
-0.45458984375,
-0.349365234375,
0.5126953125,
0.28076171875,
0.480712890625,
0.67529296875,
-0.55126953125,
0.1051025390625,
-0.5009765625,
-0.133544921875,
0.12030029296875,
-0.01287841796875,
-0.5... | 33 |
Please summerize the given abstract to a title
Homeopathic Treatment for COVID-19-Related Symptoms: A Case Series
BACKGROUND: Severe acute respiratory syndrome due to coronavirus 2 (SARS CoV-2) is a novel infectious disease, which has quickly developed into a pandemic. The spectrum of COVID-19 symptoms is broad, ranging from a mild, self-limiting respiratory tract illness to severe progressive pneumonia, multi-organ failure and possible death. Despite much effort and multiple clinical trials, there are, to date, no specific therapeutic agents to treat or cure the coronavirus infection. CASE REPORTS: The present paper presents 5 cases of patients with moderate to severe COVID-19 infections, 2 of them hospitalized in the intensive care unit, who were successfully treated with homeopathy. RESULTS: All 5 patients responded to homeopathic treatment in an unexpectedly short time span, improving both physically and mentally. CONCLUSION: The present case series emphasizes the rapidity of response among moderate to severely ill patients to homeopathic treatment, when conventional medical options have been unable to relieve or shorten the disease. The observations described should encourage use of homeopathy in treating patients with COVID-19 during the acute phase of the disease.
| 78,265 | [
0.01494598388671875,
-0.09808349609375,
-0.13427734375,
0.31787109375,
-0.669921875,
-0.1053466796875,
-0.1412353515625,
0.32421875,
0.50146484375,
0.320556640625,
0.54931640625,
-0.61767578125,
0.059814453125,
-0.68115234375,
-0.28564453125,
-0.352294921875,
-0.310302734375,
-0.90... | 33 |
Please summerize the given abstract to a title
Open Questions for Harnessing Autophagy-Modulating Drugs in the SARS-CoV-2 War
At a time when the world faces an emotional breakdown, crushing our dreams if not taking our lives, we realize that together we must fight the war against the COVID-19 outbreak even if almost the majority of the scientific community finds itself confined to home. Every day, like everyone else, we, scientists, listen to the latest news with its promises and announcements. Across the world, a surge of clinical trials trying to cure or slow down the coronavirus pandemic has been launched to bring hope instead of fear and despair. One of the most recent has drawn worldwide hype to the possible benefit of chloroquine (CQ), a well-known and broadly used anti-malarial drug, in the treatment of patients infected by the recently emerged deadly coronavirus (SARS-CoV-2). We should consider this information in the light of the long-standing anti-inflammatory and anti-viral properties of CQ-related drugs. Yet, none of these articles evoked a possible molecular or cellular mechanism of action that could account for any efficacy. Here, given the interaction of viruses with macroautophagy (hereafter referred to as autophagy), a CQ-sensitive anti-viral safeguard pathway, we would like to discuss some pros and cons concerning the current therapeutic options targeting this process.
| 78,288 | [
0.5654296875,
-0.05474853515625,
-0.044708251953125,
1.1533203125,
-0.473876953125,
0.027740478515625,
-0.72705078125,
0.4541015625,
0.48193359375,
0.429931640625,
0.1759033203125,
-0.81396484375,
-0.1964111328125,
-0.51171875,
-0.2440185546875,
0.43359375,
0.04547119140625,
-0.272... | 33 |
Please summerize the given abstract to a title
COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach
BACKGROUND: The novel Coronavirus SARS-CoV-2, which was identified after a recent outbreak in Wuhan, China, in December 2019, has generated a global pandemic impacting over 200 countries around the world. Recent reports suggest that ACE2, which is the target protein to invade the host, has a ubiquitous presence in human organs, including lung parenchyma, gastrointestinal tract, nasal mucosa, renal and urinary tract, airway epithelia, lymphoid tissues, reproductive organs, vascular endothelium and neurons. In this scenario, neurologists are particularly involved into considering even more specific therapeutic strategies according to the available data during the pandemic. In particular, MS patients are usually receiving disease-modifying therapies (DMTs) with immunosuppressant or immunomodulatory effects, which increase the risk of infections and morbidity, compared with the general population. Development of PML or other serious opportunistic infections during treatment with natalizumab forces to consider whether de-risking strategies are needed in this particular context and how to manage a high-efficacy treatment. METHODS: In this paper we report on a patient treated with natalizumab for relapsing MS who developed COVID-19 and recovered in a few days without complications. RESULTS: After recovery natalizumab has been administered in the window of the extended interval dosing (EID), without reporting any worsening or new symptoms. DISCUSSION: This case supports the opportunity to avoid discontinuing or delaying the retreatment over 8 weeks in patients recovered from a recent COVID-19.
| 78,298 | [
0.04302978515625,
0.0135955810546875,
-0.1859130859375,
0.45654296875,
-0.8486328125,
-0.4375,
-0.471923828125,
0.39453125,
0.193115234375,
0.2626953125,
0.1787109375,
-0.63916015625,
-0.184814453125,
-0.51318359375,
-0.72119140625,
0.58544921875,
-0.5810546875,
-0.6728515625,
-0... | 33 |
Please summerize the given abstract to a title
Interleukin‐6 Receptor Antagonist Therapy to Treat SARS‐CoV‐2 Driven Inflammatory Syndrome in a Renal Transplant Recipient
Coronavirus disease 2019 (COVID‐19) caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a pandemic that is evolving rapidly at present with unprecedented global health and societal implications. Herein, we report a case of successful treatment of SARS‐CoV‐2 induced inflammatory syndrome by utilization of the interleukin‐6 receptor antagonist (IL‐6Ra) tocilizumab.
| 78,377 | [
0.006439208984375,
0.10174560546875,
-0.015594482421875,
0.183837890625,
-0.72216796875,
-0.07330322265625,
-0.311279296875,
0.771484375,
0.359375,
0.50341796875,
-0.212158203125,
-0.430908203125,
-0.037078857421875,
-0.052154541015625,
-0.46142578125,
0.0689697265625,
0.037750244140... | 33 |
Please summerize the given abstract to a title
Arginine depletion as a therapeutic approach for patients with COVID-19
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a source of significant morbidity and death worldwide, and effective treatments are urgently needed. Clinical trials have focused largely on direct antiviral therapies or on immunomodulation in patients with severe manifestations of COVID-19. One therapeutic approach that remains to be clinically investigated is disruption of the host-virus relationship through amino acid restriction, a strategy used successfully in the setting of cancer treatment. Arginine is an amino acid that has been shown in nonclinical studies to be essential in the life cycle of many viruses. Therefore, arginine depletion may be an effective therapeutic approach against SARS-CoV-2. Several arginine-metabolizing enzymes in clinical development may be a viable approach to induce a low arginine environment to treat COVID-19 and other viral diseases. Herein, we explore the rationale for arginine depletion as a therapeutic approach for COVID-19.
| 78,453 | [
0.274658203125,
-0.170654296875,
0.1839599609375,
0.8623046875,
-0.865234375,
-0.274658203125,
-0.061279296875,
0.2724609375,
0.336181640625,
0.6376953125,
0.2471923828125,
-0.81103515625,
0.28662109375,
-0.537109375,
-0.393310546875,
0.431884765625,
-0.2203369140625,
-0.5986328125... | 33 |
Please summerize the given abstract to a title
Therapeutic Options for Treatment of COVID-19: A Review from Repur-posed Drugs to New Drug Targets.
A new virus pandemic, COVID-19, has instigated substantial damage to human wellness in terms of death and ailment, economic compromises along with restriction of daily routine life. There is a profound increase in the number of victims and causalities day by day. Thus far, there is no available treatment and vaccination for COVID-19. Under the rapid pace of clinical research work, scientists have reported different drugs having in vitro efficacy against COVID-19. But the evidences for their in vivo use have not been established yet in terms of clinical effect, duration of stay in intensive care units as well as the refuge of these drugs and their combinations. Anti-retroviral, Remdesivir, as well as different repurposed drugs like chloroquine and hydroxychloroquine have shown promising effects in vitro. Numerous clinical tests are underway in order to explore the benefits of these drugs. This review covers the disease pathogenesis and various potential targets with reference to the virulence of COVID-19.
| 78,584 | [
0.346923828125,
-0.36767578125,
-0.068359375,
0.6591796875,
-0.66455078125,
-0.2183837890625,
-0.405029296875,
0.456298828125,
0.54296875,
0.19384765625,
0.7919921875,
-0.873046875,
0.1572265625,
-0.3203125,
-0.1002197265625,
0.297119140625,
-0.5634765625,
-0.97998046875,
-0.2143... | 33 |
Please summerize the given abstract to a title
Ivermectin the Promising Drug to Stave off the COVID-19 Crisis: A Review
The Coronavirus disease 2019 (COVID-19) outbreak, forcing us to face unprecedented moments in the world The huge devastating impact of the world due to the covid-19 attack causes the brink of no return However, there is no proven and specific treatment for Covid -19 Very few medications have received Emergency Use of Authorization A recent in vitro study was the first time to find out and to assess the antiviral effect of Ivermectin on COVID-19 The study showed that Ivermectin was active against COVID- 19-infected cells, was able to kill effectively almost all viral particles within 48 h In these moments of crisis, FDA-approved ivermectin is a ray of hope
| 78,596 | [
0.3134765625,
-0.53173828125,
-0.59619140625,
0.3330078125,
-0.288818359375,
-0.0845947265625,
-0.06817626953125,
0.39990234375,
0.300048828125,
0.41796875,
0.459716796875,
-0.55322265625,
-0.0701904296875,
-0.77099609375,
-0.257080078125,
0.6142578125,
-0.2210693359375,
-0.7695312... | 33 |
Please summerize the given abstract to a title
Metabolic Reprogramming in COVID-19
Plenty of research has revealed virus induced alternations in metabolic pathways, which is known as metabolic reprogramming. Studies focusing on COVID-19 have uncovered significant changes in metabolism, resulting in the perspective that COVID-19 is a metabolic disease. Reprogramming of amino acid, glucose, cholesterol and fatty acid is distinctive characteristic of COVID-19 infection. These metabolic changes in COVID-19 have a critical role not only in producing energy and virus constituent elements, but also in regulating immune response, offering new insights into COVID-19 pathophysiology. Remarkably, metabolic reprogramming provides great opportunities for developing novel biomarkers and therapeutic agents for COVID-19 infection. Such novel agents are expected to be effective adjuvant therapies. In this review, we integrate present studies about major metabolic reprogramming in COVID-19, as well as the possibility of targeting reprogrammed metabolism to combat virus infection.
| 78,701 | [
0.23681640625,
-0.79541015625,
-0.603515625,
0.63427734375,
-0.51708984375,
-0.2232666015625,
0.046173095703125,
-0.06744384765625,
-0.17724609375,
0.64013671875,
0.339599609375,
-0.405517578125,
0.422607421875,
-0.76171875,
-0.424072265625,
0.1546630859375,
-0.42041015625,
-0.7402... | 33 |
Please summerize the given abstract to a title
Role of Polypeptide Inflammatory Biomarkers in the Diagnosis and Monitoring of COVID-19
The COVID-19 (coronavirus disease 2019) pandemic that took over the world in December 2019 has had everlasting devastating impacts on the lives of people globally. It manifests a huge symptom spectrum ranging from asymptomatic to critically ill patients with an unpredictable outcome. Timely diagnosis and assessment of disease severity is imperative for effective treatment. Possibilities exist that by the time symptoms appear the viral load might increase beyond control. However, it is advisable to get adequately diagnosed as soon as the first symptom appears. There is an immediate requirement of reliable biomarkers of COVID-19 manifesting an early onset for effective clinical management, stratification of high risk patients and ensuring ideal resource allocation. In this review, we attempt to explore and describe important polypeptide inflammatory biomarkers, namely C-reactive protein, Procalcitonin, Ferritin, Lactate Dehydrogenase, Serum amyloid A, Interleukin-6, Tumor necrosis factor-alpha and LIGHT used in the detection and management of COVID-19. Viral pathogenesis and the role of these inflammatory biomarkers is highlighted, based on the evidences available till date. An integrative data monitoring along with their correlation with the natural disease progression is of utmost importance in the management of COVID-19. So further research and in-depth analysis of these biomarkers is warranted in the present scenario.
| 78,719 | [
0.239990234375,
-0.2454833984375,
-0.019439697265625,
0.669921875,
-0.9208984375,
-0.40625,
-0.237060546875,
0.169189453125,
0.64013671875,
0.53125,
-0.017059326171875,
-0.50927734375,
0.017425537109375,
-0.3955078125,
-0.344482421875,
-0.0213470458984375,
-0.70556640625,
-0.622558... | 33 |
Please summerize the given abstract to a title
COVID-19: Review of a 21st Century Pandemic from Etiology to Neuro-psychiatric Implications
COVID-19 is a severe infectious disease that has claimed >150,000 lives and infected millions in the United States thus far, especially the elderly population. Emerging evidence has shown the virus to cause hemorrhagic and immunologic responses, which impact all organs, including lungs, kidneys, and the brain, as well as extremities. SARS-CoV-2 also affects patients’, families’, and society’s mental health at large. There is growing evidence of re-infection in some patients. The goal of this paper is to provide a comprehensive review of SARS-CoV-2-induced disease, its mechanism of infection, diagnostics, therapeutics, and treatment strategies, while also focusing on less attended aspects by previous studies, including nutritional support, psychological, and rehabilitation of the pandemic and its management. We performed a systematic review of >1,000 articles and included 425 references from online databases, including, PubMed, Google Scholar, and California Baptist University’s library. COVID-19 patients go through acute respiratory distress syndrome, cytokine storm, acute hypercoagulable state, and autonomic dysfunction, which must be managed by a multidisciplinary team including nursing, nutrition, and rehabilitation. The elderly population and those who are suffering from Alzheimer’s disease and dementia related illnesses seem to be at the higher risk. There are 28 vaccines under development, and new treatment strategies/protocols are being investigated. The future management for COVID-19 should include B-cell and T-cell immunotherapy in combination with emerging prophylaxis. The mental health and illness aspect of COVID-19 are among the most important side effects of this pandemic which requires a national plan for prevention, diagnosis and treatment.
| 78,750 | [
0.0278472900390625,
-0.1705322265625,
-0.26318359375,
0.75244140625,
-0.461669921875,
-0.2294921875,
-0.280029296875,
0.282470703125,
0.1923828125,
0.56689453125,
0.16943359375,
-1.0078125,
0.006610870361328125,
-0.318603515625,
-0.0304107666015625,
-0.0687255859375,
-0.440673828125,... | 33 |
Please summerize the given abstract to a title
Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China
A novel coronavirus (2019-nCoV) originating in Wuhan, China presents a potential respiratory viral pandemic to the world population. Current efforts are focused on containment and quarantine of infected individuals. Ultimately, the outbreak could be controlled with a protective vaccine to prevent 2019-nCoV infection. While vaccine research should be pursued intensely, there exists today no therapy to treat 2019-nCoV upon infection, despite an urgent need to find options to help these patients and preclude potential death. Herein, I review the potential options to treat 2019-nCoV in patients, with an emphasis on the necessity for speed and timeliness in developing new and effective therapies in this outbreak. I consider the options of drug repurposing, developing neutralizing monoclonal antibody therapy, and an oligonucleotide strategy targeting the viral RNA genome, emphasizing the promise and pitfalls of these approaches. Finally, I advocate for the fastest strategy to develop a treatment now, which could be resistant to any mutations the virus may have in the future. The proposal is a biologic that blocks 2019-nCoV entry using a soluble version of the viral receptor, angiotensin-converting enzyme 2 (ACE2), fused to an immunoglobulin Fc domain (ACE2-Fc), providing a neutralizing antibody with maximal breath to avoid any viral escape, while also helping to recruit the immune system to build lasting immunity. The ACE2-Fc therapy would also supplement decreased ACE2 levels in the lungs during infection, thereby directly treating acute respiratory distress pathophysiology as a third mechanism of action. The sequence of the ACE2-Fc protein is provided to investigators, allowing its possible use in recombinant protein expression systems to start producing drug today to treat patients under compassionate use, while formal clinical trials are later undertaken. Such a treatment could help infected patients before a protective vaccine is developed and widely available in the coming months to year(s).
| 78,783 | [
-0.1409912109375,
-0.13916015625,
-0.251220703125,
0.343505859375,
-0.56005859375,
-0.76611328125,
-0.228515625,
0.4775390625,
0.06414794921875,
0.276123046875,
0.2027587890625,
-0.327880859375,
0.04931640625,
-0.6787109375,
-0.6015625,
0.172607421875,
-0.224365234375,
-0.522460937... | 33 |
Please summerize the given abstract to a title
Therapeutic Potential of Metformin in COVID-19: Reasoning for Its Protective Role
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections present with increased disease severity and poor clinical outcomes in diabetic patients compared with their nondiabetic counterparts. Diabetes/hyperglycemia-triggered endothelial dysfunction and hyperactive inflammatory and immune responses are correlated to twofold to threefold higher intensive care hospitalizations and more than twice the mortality among diabetic coronavirus disease 2019 (COVID-19) patients. While comorbidities such as obesity, cardiovascular disease, and hypertension worsen the prognosis of diabetic COVID-19 patients, COVID-19 infections are also associated with new-onset diabetes, severe metabolic complications, and increased thrombotic events in the backdrop of aberrant endothelial function. While several antidiabetic medications are used to manage blood glucose levels, we discuss the multifaceted ability of metformin to control blood glucose levels and possibly attenuate endothelial dysfunction, inhibit viral entry and infection, and modify inflammatory and immune responses during SARS-CoV-2 infections. These actions make metformin a viable candidate drug to be considered for repurposing and gaining ground against the SARS-CoV-2-induced tsunami in diabetic COVID-19 patients.
| 78,823 | [
0.38671875,
0.1749267578125,
0.0186920166015625,
0.74365234375,
-1.0400390625,
-0.206298828125,
-0.37841796875,
0.4501953125,
0.26220703125,
0.57470703125,
0.17431640625,
-0.7001953125,
0.50830078125,
-0.5673828125,
-0.1409912109375,
0.5947265625,
-0.340087890625,
-0.51171875,
0.... | 33 |
Please summerize the given abstract to a title
Lithium and coronaviral infections. A scoping review.
The current rapid spread of the novel coronavirus (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) calls for a rapid response from the research community. Lithium is widely used to treat bipolar disorder, but has been shown to exhibit antiviral activity. This brief review took a systematic approach to identify six in vitro studies reporting on the influence of lithium on coronaviral infections. We propose mechanistic investigation of the influence of lithium - alone and with chloroquine - on the SARS-CoV-2 infection.
| 79,000 | [
-0.09619140625,
-0.1495361328125,
-0.08978271484375,
0.470703125,
-0.71630859375,
0.054168701171875,
-0.33935546875,
0.638671875,
0.176025390625,
0.68310546875,
0.39794921875,
-0.64111328125,
0.007320404052734375,
-0.5498046875,
-0.0711669921875,
-0.12335205078125,
-0.2529296875,
-... | 33 |
Please summerize the given abstract to a title
Management of SARS-CoV-2 Infection: Key Focus in Macrolides Efficacy for COVID-19
Macrolides (e g , erythromycin, fidaxomicin, clarithromycin, and azithromycin) are a class of bacteriostatic antibiotics commonly employed in medicine against various gram-positive and atypical bacterial species mostly related to respiratory tract infections, besides they possess anti-inflammatory and immunomodulatory effects Coronavirus Disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome of coronavirus 2 (SARS-CoV-2) It was first detected in Wuhan, Hubei, China, in December 2019 and resulted in a continuing pandemic Macrolides have been extensively researched as broad adjunctive therapy for COVID-19 due to its immunostimulant abilities Among such class of drugs, azithromycin is described as azalide and is well-known for its ability to decrease the production of pro-inflammatory cytokines, including matrix metalloproteinases, tumor necrosis factor-alpha, interleukin (IL)-6, and IL-8 In fact, a report recently published highlighted the effectiveness of combining azithromycin and hydroxychloroquine for COVID-19 treatment Indeed, it has been underlined that azithromycin quickly prevents SARS-CoV-2 infection by raising the levels of both interferons and interferon-stimulated proteins at the same time which reduces the virus replication and release In this sense, the current review aims to evaluate the applications of macrolides for the treatment of COVID-19
| 79,148 | [
0.2293701171875,
0.0009393692016601562,
-0.046844482421875,
0.269287109375,
-1.1943359375,
0.1890869140625,
-0.2958984375,
0.08111572265625,
0.00926971435546875,
0.701171875,
0.240478515625,
-0.406982421875,
-0.12054443359375,
-0.251708984375,
-0.366455078125,
-0.019195556640625,
-0.... | 33 |
Please summerize the given abstract to a title
Gene therapies and COVID-19 vaccines: a necessary discussion in relation with viral vector-based approaches
The COVID-19 pandemic is adding an unanticipated concern for those affected by genetic diseases. Most of the new treatment achievements for these patients are made possible as a result of advances in viral-based products. Among them, adenoviruses (AdV) and especially adeno-associated viruses (AAV) are important players. The concerns and the conversation around this issue have increased as COVID-19 vaccines approach the market. What if the viral vectors become the mainstream strategy for vaccine development? Will the immune response elicited against the vector compromise the efficacy of future gene therapies? Patients with genetic diseases and patient advocacy groups are requesting information to the medical community about the potential impact of these vaccines in future gene therapy treatments, and physicians and scientists are not able to provide satisfactory answer yet. Importantly, the frequency of cross-reactivity among different AAV serotypes can be as high as 50%. This would have potential implications for patients with genetic disorders who could benefit from gene therapies, often coming in the form of AAV-based gene therapies. As in many other aspects, this pandemic is challenging our capacity to coordinate, plan ahead and align different medical objectives. In this case, having such conversation early on might allow us to make the right choices while we are still on time.
| 79,407 | [
0.4912109375,
-0.1705322265625,
-0.387451171875,
0.7275390625,
-0.37646484375,
-0.482177734375,
-0.51708984375,
-0.0005078315734863281,
0.12939453125,
0.2205810546875,
-0.131591796875,
-0.7646484375,
0.099853515625,
-0.433837890625,
-0.537109375,
-0.0220489501953125,
-0.332275390625,... | 33 |
Please summerize the given abstract to a title
Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections
The recent Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak poses a serious threat to public health. Here, we summarize recent advances in identifying human neutralizing monoclonal antibodies (mAbs) against MERS-CoV, describe their mechanisms of action, and analyze their potential for treatment of MERS-CoV infections.
| 79,451 | [
0.0294952392578125,
-0.20947265625,
-0.53125,
0.5224609375,
-0.312255859375,
-0.2210693359375,
-0.4736328125,
0.548828125,
0.324462890625,
0.1663818359375,
0.10546875,
-0.2147216796875,
-0.33203125,
-0.6552734375,
-0.79541015625,
-0.341064453125,
-0.08099365234375,
-0.57763671875,
... | 33 |
Please summerize the given abstract to a title
Evolutionary artificial intelligence based peptide discoveries for effective Covid-19 therapeutics
An epidemic caused by COVID-19 in China turned into pandemic within a short duration affecting countries worldwide. Researchers and companies around the world are working on all the possible strategies to develop a curative or preventive strategy for the same, which includes vaccine development, drug repurposing, plasma therapy, and drug discovery based on Artificial intelligence. Therapeutic approaches based on Computational biology and Machine-learning algorithms are specially considered, with a view that these could provide a fast and accurate outcome in the present scenario. As an effort towards developing possible therapeutics for COVID-19, we have used machine-learning algorithms for the generation of alignment kernels from diverse viral sequences of Covid-19 reported from India, China, Italy and USA. Using these diverse sequences we have identified the conserved motifs and subsequently a peptide library was designed against them. Of these, 4 peptides have shown strong binding affinity against the main protease of SARS-CoV-2 (Mpro) and also maintained their stability and specificity under physiological conditions as observed through MD Simulations. Our data suggest that these evolutionary peptides against COVID-19 if found effective may provide cross-protection against diverse Covid-19 variants.
| 79,470 | [
-0.0239105224609375,
0.1358642578125,
-0.2293701171875,
0.440673828125,
-0.359375,
-0.2047119140625,
-0.48388671875,
0.1646728515625,
0.41162109375,
0.66845703125,
0.1485595703125,
-0.36962890625,
-0.3046875,
-0.59423828125,
-0.73876953125,
0.109130859375,
-0.360595703125,
-0.66650... | 33 |
Please summerize the given abstract to a title
A comprehensive update on the structure and synthesis of potential drug targets for combating the coronavirus pandemic caused by SARS‐CoV‐2
The outbreak of the coronavirus pandemic COVID‐19 created by its severe acute respiratory syndrome corona virus‐2 (SARS‐CoV‐2) variant, known for producing a very severe acute respiratory syndrome, has created an unprecedented situation by its continual assault around the world. The crisis caused by the SARS‐CoV‐2 variant has been a global challenge, calling to mitigate this unprecedented pandemic that has engulfed the whole world. Since the outbreak and spread of COVID‐19, many researchers globally have been grappling to find new clinically trialed active drugs with anti‐COVID‐19 activity, from antimalarial drugs to JAK inhibitors, antiviral drugs, immune suppressants, and so forth. This article presents a brief discussion on the activity and synthesis of some active molecules such as favipiravir, hydroxychloroquine, pirfenidone, remdesivir, lopinavir, camostat, chloroquine, baricitinib, molnupiravir, and so forth, which are under trial.
| 79,541 | [
0.146728515625,
0.283203125,
-0.161376953125,
0.6669921875,
-0.6630859375,
-0.09832763671875,
-0.67822265625,
0.439453125,
0.53125,
0.2978515625,
0.6123046875,
-0.5703125,
-0.0108489990234375,
-0.9013671875,
-0.5322265625,
0.61962890625,
-0.454833984375,
-0.62109375,
0.2563476562... | 33 |
Please summerize the given abstract to a title
SUMO: a novel target for anti-coronavirus therapy.
Over the past 20 years, humankind has encountered three severe coronavirus outbreaks. Currently ongoing, COVID-19 (coronavirus disease 2019) was declared a pandemic due to its massive impact on global health and the economy. Numerous scientists are working to identify efficacious therapeutic agents for COVID-19, although treatment ability has yet to be demonstrated. The SUMO (small ubiquitin-like modifier) system has diverse roles in viral manipulation, but the function of SUMO in coronaviruses is still unknown. The objective of this review article is to present recently published data suggesting contributions of the host SUMO system to coronavirus infection. These findings underscore the potential of SUMO as a novel target for anti-coronavirus therapy, and the need for a deeper understanding of coronavirus pathology to prepare and prevail against the current and emerging coronavirus outbreaks.
| 79,623 | [
0.3056640625,
-0.151611328125,
-0.2110595703125,
0.6865234375,
-0.353271484375,
-0.06787109375,
-0.330810546875,
0.2958984375,
0.47021484375,
0.2430419921875,
0.478515625,
-0.642578125,
0.0233154296875,
-0.638671875,
-0.2369384765625,
0.08428955078125,
-0.191162109375,
-0.752929687... | 33 |
Please summerize the given abstract to a title
Convalescent plasma: A possible treatment of COVID-19 in India
In India, SARS-CoV-2 virus-induced coronavirus disease 2019 (COVID-19) has already infected close to 5500 people, causing the death of 164. While these numbers are not comparable with values observed for the USA, Italy, or Spain, given the population of India, and the fact that the pandemic is now in an exponential stage of growth, the risks of a contagion that affects a large sector of the Indian population are real. There are no current effective strategies to prevent the spread, other than minimizing contact through social distancing, while no fully effective drugs to prevent or treat COVID-19 exist, although several candidate drugs and repurposed antiviral and immune-modulating pharmacotherapies are being tested or in compassionate use. One postexposure prophylaxis, convalescent (immune) plasma (CP), has shown some success in China and previously in the cure and therapy of other coronaviruses, SARS-1 and Middle East respiratory syndrome. Drawn from current patients who are infected with COVID-19, its CP (human anti-SARS-CoV-2 plasma) might be one way to modulate the infectivity of this virus or its effects postinfection.
| 79,676 | [
-0.302734375,
-0.16259765625,
-0.5439453125,
0.58203125,
-0.87060546875,
-0.433837890625,
-0.708984375,
0.60693359375,
0.5263671875,
0.390380859375,
0.032745361328125,
-0.299560546875,
-0.058319091796875,
-0.5400390625,
-0.2252197265625,
0.08740234375,
-0.556640625,
-0.5888671875,
... | 33 |
Please summerize the given abstract to a title
Antiviral activity of molnupiravir against COVID-19: a schematic review of evidences
BACKGROUND: The study was aimed at encapsulating the evidence of in vitro and in vivo antiviral activities of molnupiravir and its active form against highly pathogenic SARS-CoV-2, the pathogen responsible for COVID-19, and finding out the efficacy and safety of molnupiravir in clinical trials. MAIN BODY: Information on publications was explored on several databases, gray literature was reviewed, and the outcomes were discussed narratively. Molnupiravir's antiviral efficacy and associated mechanism of action have been verified in vitro against both non-COVID and multiple coronaviruses. Molnupiravir has been tried in preclinical investigations in numerous animal models against non-coronaviruses. Clinical studies in several countries are now being conducted to evaluate its antiviral efficacy in persons infected with COVID-19. The medication displays antiviral effect via generation of copying mistakes during viral RNA replication. CONCLUSIONS: Molnupiravir is the first oral antiviral medicine to show considerable and convincing antiviral activity in vitro and in animal models. Molnupiravir stops the spread of SARS-CoV-2 in animals that have been infected and in cells grown in a lab. In a clinical research, early molnupiravir treatment reduced hospitalization and death risk in unvaccinated individuals with COVID-19. In the battle against SARS-CoV-2, it could be a potent weapon. However, its role in COVID-19 in moderate to severe cases is still up in the air, and more research is needed.
| 79,940 | [
0.2685546875,
-0.3056640625,
-0.380615234375,
0.367919921875,
-0.427490234375,
-0.0203094482421875,
-0.373779296875,
0.51513671875,
0.5146484375,
0.85693359375,
0.362060546875,
-0.378662109375,
0.1571044921875,
-0.366455078125,
-0.461181640625,
0.5107421875,
-0.144775390625,
-0.770... | 33 |
Please summerize the given abstract to a title
Immunology and controlling of coronaviruses; the current enemy for humanity: A review
The Severe Acute Respiratory Syndrome-related Coronavirus 2 (COVID-19 or SARS-CoV-2) epidemic is professed as world disaster producing a worrying increasing mortality, particularly amongst vulnerable humans worldwide. Whether COVID-19 has a strong ability for acceptable genetic flexibility that amended for breaking immune responses quickly, it is critical to understand the adaptation mechanism between viruses and hosts that allows individuals to follow viral development. This can contribute to finding the appropriate treatment to combat the epidemic. However, the present information about viral adaptation mechanisms in hosts is still insufficient, and future investigations may reveal the unknown. Mutations and genetic variations are naturally occurring; however, the current knowledge about their mechanism and pathways still has many secrets. The present review also provides insights into the immune system, immunological memory, and the development of the COVID-19 vaccine. Other fighting methods against COVID-19 are also highlighted. The potential of antibodies, natural metabolites, and current suggest vaccines were applied to the face of this new threat.
| 79,955 | [
0.0513916015625,
0.294189453125,
-0.436279296875,
0.51513671875,
-0.5654296875,
-0.258056640625,
-0.469970703125,
0.5400390625,
0.0726318359375,
0.371337890625,
0.346435546875,
-0.197998046875,
-0.003803253173828125,
-0.52001953125,
-0.407470703125,
-0.2021484375,
-0.381103515625,
... | 33 |
Please summerize the given abstract to a title
How should we treat pregnant women infected with SARS‐CoV‐2?
The health crisis caused by the novel SARS-cov-2 (formally called 2019-nCoV) related pandemic requires urgent action, including a necessary therapeutic response. Pregnant women are just as exposed as the general population and should not be excluded, because of their status, from discussions on effective and well tolerated candidate treatments.
| 80,090 | [
0.3759765625,
0.047027587890625,
-0.254638671875,
0.6728515625,
-0.63720703125,
-0.218994140625,
-0.1126708984375,
0.478271484375,
0.33154296875,
0.493896484375,
0.427978515625,
-0.52783203125,
0.140380859375,
-0.6552734375,
-0.3515625,
0.263671875,
0.104248046875,
-0.74951171875,
... | 33 |
Please summerize the given abstract to a title
Food as medicine: A possible preventive measure against coronavirus disease (COVID-19)
The recent and ongoing outbreak of coronavirus disease (COVID-19) is a huge global challenge. The outbreak, which first occurred in Wuhan City, Hubei Province, China and then rapidly spread to other provinces and to more than 200 countries abroad, has been declared a global pandemic by the World Health Organization. Those with compromised immune systems and/or existing respiratory, metabolic or cardiac problems are more susceptible to the infection and are at higher risk of serious illness or even death. The present review was designed to report important functional food plants with immunomodulatory and anti-viral properties. Data on medicinal food plants were retrieved and downloaded from English-language journals using online search engines. The functional food plants herein documented might not only enhance the immune system and cure respiratory tract infections but can also greatly impact the overall health of the general public. As many people in the world are now confined to their homes, inclusion of these easily accessible plants in the daily diet may help to strengthen the immune system and guard against infection by SARS-CoV-2. This might reduce the risk of COVID-19 and initiate a rapid recovery in cases of SARS-CoV-2 infection.
| 80,188 | [
-0.158203125,
-0.060302734375,
-0.086669921875,
0.8369140625,
-0.369140625,
-0.1640625,
-0.031280517578125,
0.73828125,
0.47216796875,
0.495849609375,
0.53125,
-0.58740234375,
-0.07049560546875,
-0.5908203125,
-0.421142578125,
0.0165252685546875,
-0.33837890625,
-0.80322265625,
0... | 33 |
Please summerize the given abstract to a title
The advantages of drug treatment with statins in patients with SARS-CoV-2 infection
On 11 March 2020 the World Health Organization (WHO) declared a status of global pandemic caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease 2019, COVID-19). The pandemic is currently underway, and to date has caused approximately 2.42 million deaths worldwide. The first vaccines have recently been licensed; however, research continues to identify therapeutic agents to prevent serious complications, such as anti-inflammatory, immunomodulatory, anticoagulant or antiviral agents authorized for other therapeutic indications. Epidemiological evidence shows that advanced age and comorbidities, such as diabetes, heart disease, and dyslipidemia may represent COVID-19 risk factors. In particular, in patients with hypercholesterolemia treated with statins, it is recommended that treatment should not be discontinued if COVID-19 infection occurs. The pleiotropic effects of statins are well known. In this brief review, we propose that the use of statins can potentially protect against SARS-CoV-2-induced tissue damage and improve lung function in COVID-19 patients through several pleiotropic effects. Pleiotropic effects of statins that may be a significant benefit in patients with hypercholesterolemia treated with statins and COVID-19 positive. Recent evidence shows promising results.
| 80,280 | [
0.19677734375,
0.3447265625,
-0.087158203125,
0.5712890625,
-0.6875,
-0.1553955078125,
-0.1793212890625,
0.544921875,
0.61474609375,
0.51904296875,
0.38330078125,
-0.93701171875,
0.0168609619140625,
-0.474609375,
-0.22412109375,
0.45703125,
-0.411865234375,
-0.63330078125,
0.2358... | 33 |
Please summerize the given abstract to a title
Drug discovery of small molecules for the treatment of COVID-19: A review on clinical studies
Recently, a sudden outbreak of novel coronavirus disease (COVID-19) was caused by a zoonotic virus known as severe acute respiratory syndrome coronavirus (SARS-CoV-2). It has caused pandemic situations around the globe and affecting the lives of millions of people. So far, no drug has been approved for the treatment of SARS-CoV-2 infected patients. As of now, more than 1000 clinical trials are going on for repurposing of FDA approved drugs and for evaluating the safety & efficiency of experimental antiviral molecules to combat COVID-19. Since the development of new drugs may require months to years to reach the market, this review focusses on the potentials of existing small molecule FDA approved drugs and the molecules already in the clinical pipeline against viral infections like HIV, hepatitis B, Ebola virus, and other viruses of coronavirus family (SARS-CoV and MERS-CoV). The review also discusses the natural products and traditional medicines in clinical studies against COVID-19. Currently, 1978 studies are active, 143 completed and 4 posted results (as on June 13, 2020) on clinicaltrials.gov.
| 80,407 | [
-0.318359375,
-0.408447265625,
-0.245849609375,
0.705078125,
-0.5966796875,
-0.039337158203125,
-0.457763671875,
0.61181640625,
0.32421875,
0.406494140625,
0.62646484375,
-0.68408203125,
-0.05517578125,
-0.638671875,
-0.2626953125,
0.44873046875,
-0.25732421875,
-0.492431640625,
... | 33 |
Please summerize the given abstract to a title
The Importance of Cellular Immunity in the Development of Vaccines and Therapeutics for COVID-19
It is important to develop vaccines that can also mediate T-cell responses to SARS-CoV-2 to limit severity of infections, and to analyze the cellular immunome in the use of anti-SARS-CoV-2 therapeutics.
| 80,410 | [
0.609375,
-0.2388916015625,
-0.379638671875,
0.1204833984375,
-0.257568359375,
0.1112060546875,
-0.2413330078125,
0.3310546875,
-0.022369384765625,
0.34716796875,
0.06732177734375,
-0.0687255859375,
0.09002685546875,
-0.3544921875,
-0.00445556640625,
-0.275146484375,
-0.048583984375,... | 33 |
Please summerize the given abstract to a title
Drug repurposing against COVID-19: focus on anticancer agents
BACKGROUND: The very limited time allowed to face the COVID-19 pandemic poses a pressing challenge to find proper therapeutic approaches. However, synthesis and full investigation from preclinical studies to phase III trials of new medications is a time-consuming procedure, and not viable in a global emergency, such as the one we are facing. MAIN BODY: Drug repurposing/repositioning, a strategy effectively employed in cancer treatment, can represent a valid alternative. Most drugs considered for repurposing/repositioning in the therapy of the COVID-19 outbreak are commercially available and their dosage and toxicity in humans is well known, due to years (or even decades) of clinical use. This can allow their fast-track evaluation in phase II–III clinical trials, or even within straightforward compassionate use. Several drugs being re-considered for COVID-19 therapy are or have been used in cancer therapy. Indeed, virus-infected cells are pushed to enhance the synthesis of nucleic acids, protein and lipid synthesis and boost their energy metabolism, in order to comply to the “viral program”. Indeed, the same features are seen in cancer cells, making it likely that drugs interfering with specific cancer cell pathways may be effective as well in defeating viral replication. SHORT CONCLUSION: To our knowledge, cancer drugs potentially suitable for facing SARS-CoV-2 infection have not been carefully reviewed. We present here a comprehensive analysis of available information on potential candidate cancer drugs that can be repurposed for the treatment of COIVD-19.
| 80,423 | [
0.62353515625,
-0.336669921875,
-0.27880859375,
0.57666015625,
-0.58984375,
-0.3427734375,
-0.544921875,
0.203125,
0.357177734375,
0.285400390625,
0.475830078125,
-1.0595703125,
0.1385498046875,
-0.53173828125,
-0.09393310546875,
0.322265625,
-0.4326171875,
-0.27099609375,
0.2644... | 33 |
Please summerize the given abstract to a title
Combating COVID-19: Study of robotic solutions for COVID-19
Due to the ongoing coronavirus pandemic caused by the novel virus SARS-CoV-2, the healthcare professionals throughout the world are at the most significant risk of infection from the treatment of infected patients. The risk is not only limited to them, people working in the service sectors who are required to go out and various other commercial institutions are also at economic risks due to the immobilization of resources and workforces. This report deals with the brief overview of the current and potential applications of robotics and automation in healthcare, education, and various industries that prove beneficial not only in the decline of transmission of COVID-19 by maintaining social distancing but also in carrying out tasks more safely and effectively. © 2021 Author(s).
| 80,478 | [
0.2384033203125,
0.1448974609375,
-0.765625,
0.7294921875,
-0.404296875,
-0.1627197265625,
-0.447998046875,
0.58349609375,
0.281005859375,
0.7373046875,
0.27783203125,
-0.39697265625,
0.0189056396484375,
-0.42529296875,
-0.70068359375,
-0.08563232421875,
-0.10443115234375,
-0.50390... | 33 |
Please summerize the given abstract to a title
Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2
The spread of new coronavirus infection starting December 2019 as novel SARS-CoV-2, identified as the causing agent of COVID-19, has affected all over the world and been declared as pandemic. Approximately, more than 8,807,398 confirmed cases of COVID-19 infection and 464,483 deaths have been reported globally till the end of 21 June 2020. Until now, there is no specific drug therapy or vaccine available for the treatment of COVID-19. However, some potential antimalarial drugs like hydroxychloroquine and azithromycin, antifilarial drug ivermectin and antiviral drugs have been tested by many research groups worldwide for their possible effect against the COVID-19. Hydroxychloroquine and ivermectin have been identified to act by creating the acidic condition in cells and inhibiting the importin (IMPα/β1) mediated viral import. There is a possibility that some other antimalarial drugs/antibiotics in combination with immunomodulators may help in combatting this pandemic disease. Therefore, this review focuses on the current use of various drugs as single agents (hydroxychloroquine, ivermectin, azithromycin, favipiravir, remdesivir, umifenovir, teicoplanin, nitazoxanide, doxycycline, and dexamethasone) or in combinations with immunomodulators additionally. Furthermore, possible mode of action, efficacy and current stage of clinical trials of various drug combinations against COVID-19 disease has also been discussed in detail. Communicated by Ramaswamy H. Sarma
| 80,559 | [
0.267333984375,
-0.1513671875,
-0.028594970703125,
0.5634765625,
-0.6962890625,
-0.2222900390625,
-0.048675537109375,
0.252685546875,
0.435302734375,
0.55322265625,
0.54931640625,
-0.462158203125,
0.200439453125,
-0.369873046875,
-0.29150390625,
0.484375,
-0.281982421875,
-0.808593... | 33 |
Please summerize the given abstract to a title
Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment
In the past two decades, the world has faced several infectious disease outbreaks. Ebola, Influenza A (H1N1), SARS, MERS, and Zika virus have had a massive global impact in terms of economic disruption, the strain on local and global public health. Most recently, the global outbreak of novel coronavirus 2019 (SARS-CoV-2) that causes COVID-19 is a newly discovered virus from the coronavirus family in Wuhan city, China, known to be a great threat to the public health systems. As of 15 April 2020, The Johns Hopkins University estimated that the COVID-19 affected more than two million people, resulting in a death toll above 130,000 around the world. Infected people in Europe and America correspond about 40% and 30% of the total reported cases respectively. At this moment only few Asian countries have controlled the disease, but a second wave of new infections is expected. Predicting inhibitor and target to the COVID-19 is an urgent need to protect human from the disease. Therefore, a protocol to identify anti-COVID-19 candidate based on computer-aided drug design is urgently needed. Thousands of compounds including approved drugs and drugs in the clinical trial are available in the literature. In practice, experimental techniques can measure the time and space average properties but they cannot be captured the structural variation of the COVID-19 during the interaction of inhibitor. Computer simulation is particularly suitable to complement experiments to elucidate conformational changes at the molecular level which are related to inhibition process of the COVID-19. Therefore, computational simulation is essential tool to elucidate the phenomenon. The structure-based virtual screening computational approach will be used to filter the best drugs from the literature, the investigate the structural variation of COVID-19 with the interaction of the best inhibitor is a fundamental step to design new drugs and vaccines which can combat the coronavirus. This mini-review will address novel coronavirus structure, mechanism of action, and trial test of antiviral drugs in the lab and patients with COVID-19.
| 80,581 | [
-0.1485595703125,
-0.29638671875,
0.031097412109375,
0.36181640625,
-0.314208984375,
-0.251708984375,
-0.383056640625,
0.418701171875,
-0.030181884765625,
0.58154296875,
0.3935546875,
-0.5234375,
-0.0782470703125,
-0.857421875,
-0.483154296875,
0.45556640625,
-0.1566162109375,
-0.4... | 33 |
Please summerize the given abstract to a title
Review of Trial Therapies and Treatment for COVID-19: Lessons for Indonesia
The infectious disease from Coronavirus Disease 2019, or COVID-19, has quickly spread world-wide since 2019 Therapies for managing COVID-19 have yet to be confirmed as medication for the severe sickness that the disease may cause This study aimed to review the previous research of the efficacy of trial therapy and treatment to the patients in the hospital with COVID-19 Using PRISMA guidelines as a method for conducting a systematic literature review, a total of 67 articles were collected from several online journal databases Various therapies were found that are effective in the treatment and management of COVID-19 In accordance with the inclusion and exclusion criteria of this study, a total of 8 articles were selected The study showed that several therapies are effective in managing the severe illness, can be used as COVID-19 treatment Combination of medicine have shown the effectiveness of clinical improvements and recovery rate in a short time compared to single medicine Nevertheless, further study into effective therapies for COVID-19 must be continued to find the best therapy and treatment
| 80,594 | [
0.334716796875,
-0.238525390625,
-0.56103515625,
0.439453125,
-0.74755859375,
-0.297119140625,
-0.357177734375,
0.341796875,
0.310546875,
0.89306640625,
0.2269287109375,
0.0479736328125,
-0.3076171875,
-0.6025390625,
-0.099609375,
0.0254364013671875,
-0.3310546875,
-0.7001953125,
... | 33 |
Please summerize the given abstract to a title
Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies
Coronavirus-19 (COVI-19) involves humans as well as animals and may cause serious damage to the respiratory tract, including the lung: coronavirus disease (COVID-19). This pathogenic virus has been identified in swabs performed on the throat and nose of patients who suffer from or are suspected of the disease. When COVI-19 infect the upper and lower respiratory tract it can cause mild or highly acute respiratory syndrome with consequent release of pro-inflammatory cytokines, including interleukin (IL)-1ß and IL-6. The binding of COVI-19 to the Toll Like Receptor (TLR) causes the release of pro-IL-1ß which is cleaved by caspase-1, followed by inflammasome activation and production of active mature IL-1ß which is a mediator of lung inflammation, fever and fibrosis. Suppression of pro-inflammatory IL-1 family members and IL-6 have been shown to have a therapeutic effect in many inflammatory diseases, including viral infections. Cytokine IL-37 has the ability to suppress innate and acquired immune response and also has the capacity to inhibit inflammation by acting on IL-18Rα receptor. IL-37 performs its immunosuppressive activity by acting on mTOR and increasing the adenosine monophosphate (AMP) kinase. This cytokine inhibits class II histocompatibility complex (MHC) molecules and inflammation in inflammatory diseases by suppressing MyD88 and subsequently IL-1ß, IL-6, TNF and CCL2. The suppression of IL-1ß by IL-37 in inflammatory state induced by coronavirus-19 can have a new therapeutic effect previously unknown. Another inhibitory cytokine is IL-38, the newest cytokine of the IL-1 family members, produced by several immune cells including B cells and macrophages. IL-38 is also a suppressor cytokine which inhibits IL-1ß and other pro-inflammatory IL-family members. IL-38 is a potential therapeutic cytokine which inhibits inflammation in viral infections including that caused by coronavirus-19, providing a new relevant strategy.
| 80,622 | [
-0.0264739990234375,
0.213623046875,
-0.085693359375,
0.2900390625,
-0.2763671875,
-0.1363525390625,
-0.482421875,
0.340087890625,
0.28759765625,
0.85498046875,
0.2435302734375,
-0.162353515625,
0.11700439453125,
-0.395751953125,
-0.357421875,
-0.197021484375,
-0.054229736328125,
-... | 33 |
Please summerize the given abstract to a title
Characterization of raloxifene as potential pharmacological agent against SARS-CoV-2 and its variants
The new coronavirus that emerged, called SARS-CoV-2, is the causative agent of the COVID-19 pandemic. The identification of potential drug candidates that can rapidly enter clinical trials for the prevention and treatment of COVID-19 is an urgent need, despite the recent introduction of several new vaccines for the prevention and protection of this infectious disease, which in many cases becomes severe. Drug repurposing (DR), a process for studying existing pharmaceutical products for new therapeutic indications, represents one of the most effective potential strategies employed to increase the success rate in the development of new drug therapies. We identified raloxifene, a known Selective Estrogen Receptor Modulator (SERM), as a potential pharmacological agent for the treatment of COVID-19 patients. Following a virtual screening campaign on the most relevant viral protein targets, in this work we report the results of the first pharmacological characterization of raloxifene in relevant cellular models of COVID-19 infection. The results obtained on all the most common viral variants originating in Europe, United Kingdom, Brazil, South Africa and India, currently in circulation, are also reported, confirming the efficacy of raloxifene and, consequently, the relevance of the proposed approach. Taken together, all the information gathered supports the clinical development of raloxifene and confirms that the drug can be proposed as a viable new option to fight the pandemic in at least some patient populations. The results obtained so far have paved the way for a first clinical study to test the safety and efficacy of raloxifene, just concluded in patients with mild to moderate COVID-19.
| 80,651 | [
0.186767578125,
0.006587982177734375,
0.0458984375,
0.58056640625,
-0.8369140625,
-0.51611328125,
-0.60107421875,
0.251708984375,
-0.0115814208984375,
0.167724609375,
0.298583984375,
-0.947265625,
-0.08062744140625,
-0.3681640625,
0.2073974609375,
0.53759765625,
-0.357666015625,
-0... | 33 |
Please summerize the given abstract to a title
In quest of a new therapeutic approach in COVID-19: the endocannabinoid system
The SARS-Cov-2 virus caused a high morbidity and mortality rate disease, that is the COVID-19 pandemic. Despite the unprecedented research interest in this field, the lack of specific treatments leads to severe complications in a high number of cases. Current treatment includes antivirals, corticosteroids, immunoglobulins, antimalarials, interleukin-6 inhibitors, anti-GM-CSF, convalescent plasma, immunotherapy, antibiotics, circulation support, oxygen therapy, and circulation support. Due to the limited results, until specific treatments are available, other therapeutic approaches need to be considered. The endocannabinoid system is found in multiple systems within the human body, including the immune system. Its activation can lead to beneficial results such as decreased viral entry, decreased viral replication, and a decrease in pro-inflammatory cytokines such as IL-2, IL-4, IL-6, IL-12, TNF-α, or IFN-γ. Moreover, endocannabinoid system activation can lead to an increase in anti-inflammatory cytokines, mainly represented by IL-10. Overall, the cannabinoid system can potentially reduce pulmonary inflammation, increase the immunomodulatory effect, decrease PMN infiltration, reduce fibrosis, and decrease viral replication, as well as decrease the 'cytokine storm'. Although the cannabinoid system has many mechanisms to provide certain benefits in the treatment of SARS-CoV-2 infected patients, research in this field is needed for a better understanding of the cannabinoid impact in this situation.
| 80,728 | [
0.127197265625,
-0.057769775390625,
-0.277099609375,
0.5380859375,
-0.392578125,
-0.11895751953125,
-0.371337890625,
0.82080078125,
0.1273193359375,
0.50048828125,
0.51123046875,
-0.27099609375,
0.074462890625,
-0.482421875,
-0.5595703125,
0.03900146484375,
-0.36328125,
-0.47998046... | 33 |
Please summerize the given abstract to a title
Can phytotherapy with polyphenols serve as a powerful approach for the prevention and therapy tool of novel coronavirus disease 2019 (COVID-19)?
Much more serious than the previous severe acute respiratory syndrome (SARS) coronavirus (CoV) outbreaks, the novel SARS-CoV-2 infection has spread speedily, affecting 213 countries and causing â¼17,300,000 cases and â¼672,000 (â¼+1,500/day) deaths globally (as of July 31, 2020). The potentially fatal coronavirus disease (COVID-19), caused by air droplets and airborne as the main transmission modes, clearly induces a spectrum of respiratory clinical manifestations, but it also affects the immune, gastrointestinal, hematological, nervous, and renal systems. The dramatic scale of disorders and complications arises from the inadequacy of current treatments and absence of a vaccine and specific anti-COVID-19 drugs to suppress viral replication, inflammation, and additional pathogenic conditions. This highlights the importance of understanding the SARS-CoV-2 mechanisms of actions and the urgent need of prospecting for new or alternative treatment options. The main objective of the present review is to discuss the challenging issue relative to the clinical utility of plants-derived polyphenols in fighting viral infections. Not only is the strong capacity of polyphenols highlighted in magnifying health benefits, but the underlying mechanisms are also stressed. Finally, emphasis is placed on the potential ability of polyphenols to combat SARS-CoV-2 infection via the regulation of its molecular targets of human cellular binding and replication, as well as through the resulting host inflammation, oxidative stress, and signaling pathways.
| 80,811 | [
-0.1441650390625,
-0.2225341796875,
0.069091796875,
0.98486328125,
-0.484619140625,
0.0633544921875,
-0.0467529296875,
0.513671875,
0.09478759765625,
0.410400390625,
0.312744140625,
-0.7421875,
0.339111328125,
-0.39892578125,
0.1446533203125,
0.057861328125,
0.0736083984375,
-0.371... | 33 |
Please summerize the given abstract to a title
Stopping pandemics before they start: Lessons learned from SARS-CoV-2
The vaccine and drug discovery responses to COVID-19 have worked far better than could have been imagined. Yet by the end of 2021, more than 5 million people had died, and the pandemic continues to evolve and rage globally. This Review will describe how each of the vaccines, antibody therapies, and antiviral drugs that have been approved to date were built on decades of investment in technology and basic science. We will caution that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has so far proven a straightforward test of our pandemic preparedness, and we will recommend steps we should undertake now to prepare for, to minimize the effects of, and ideally to prevent future pandemics. Other Reviews in this series describe the interactions of SARS-CoV-2 with the immune system and those therapies that target the host response to infection.
| 80,881 | [
0.18310546875,
0.1251220703125,
-0.0296630859375,
0.467529296875,
-0.2392578125,
-0.34423828125,
-0.70703125,
0.3369140625,
0.407470703125,
-0.057769775390625,
0.249755859375,
-0.63818359375,
-0.271240234375,
-0.1337890625,
-0.3310546875,
0.339599609375,
-0.2274169921875,
-0.459960... | 33 |
Please summerize the given abstract to a title
A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019)
There has been a lot of speculation that patients with coronavirus disease 2019 (COVID-19) who are receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) may be at increased risk for adverse outcomes We reviewed the available evidence, and have not found this to be the case We recommend that patients on such medications should continue on them unless there is a clinical indication to stop their use
| 80,890 | [
0.09954833984375,
-0.397705078125,
-0.0919189453125,
0.56982421875,
-0.6318359375,
-0.34912109375,
-0.058258056640625,
0.3759765625,
0.52978515625,
0.5458984375,
0.556640625,
-0.2078857421875,
-0.25439453125,
-0.7392578125,
-0.040252685546875,
0.50439453125,
-0.144287109375,
-0.610... | 33 |
Please summerize the given abstract to a title
A REVIEW on the ANTIPARASITIC DRUG IVERMECTIN for VARIOUS VIRAL INFECTIONS and POSSIBILITIES of USING IT for NOVEL SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2: NEW HOPE to TREAT CORONAVIRUS DISEASE-2019
The novel coronavirus infection has spread all over the world. With no specific drug or vaccine, the process of "drug repurposing"becomes a feasible solution. As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has 80% sequence similarity with the SARS-CoV, the nuclear import inhibitor "Ivermectin"(IVM) has recently been studied as a possible treatment option for coronavirus disease-2019 (COVID-19). The article aims to provide a review on structure and immunogenicity of SARS-CoV-2, indications of IVM for viral diseases, its possible mechanism on COVID-19 with a brief discussion on IVM structure, pharmacokinetics, adverse drug reactions, drug interactions, and contraindications. Further, we made possible comparisons of IVM with solidarity trial drugs and analyzed its major advantages, limitations and gave necessary recommendations for its use in future in vivo studies in the treatment of COVID-19.
| 80,946 | [
0.1778564453125,
0.08721923828125,
-0.056060791015625,
0.35546875,
-0.4716796875,
-0.166748046875,
-0.020904541015625,
0.318603515625,
0.059722900390625,
0.2529296875,
0.310302734375,
-0.47509765625,
0.10626220703125,
-0.6630859375,
-0.3828125,
0.388916015625,
-0.1368408203125,
-0.... | 33 |
Please summerize the given abstract to a title
Nanotechnology advances in pathogen- and host-targeted antiviral delivery: multipronged therapeutic intervention for pandemic control
The COVID-19 pandemic's high mortality rate and severe socioeconomic impact serve as a reminder of the urgent need for effective countermeasures against viral pandemic threats. In particular, effective antiviral therapeutics capable of stopping infections in its tracks is critical to reducing infection fatality rate and healthcare burden. With the field of drug delivery witnessing tremendous advancement in the last two decades owing to a panoply of nanotechnology advances, the present review summarizes and expounds on the research and development of therapeutic nanoformulations against various infectious viral pathogens, including HIV, influenza, and coronaviruses. Specifically, nanotechnology advances towards improving pathogen- and host-targeted antiviral drug delivery are reviewed, and the prospect of achieving effective viral eradication, broad-spectrum antiviral effect, and resisting viral mutations are discussed. As several COVID-19 antiviral clinical trials are met with lackluster treatment efficacy, nanocarrier strategies aimed at improving drug pharmacokinetics, biodistributions, and synergism are expected to not only contribute to the current disease treatment efforts but also expand the antiviral arsenal against other emerging viral diseases.
| 80,955 | [
0.252685546875,
-0.2088623046875,
-0.1754150390625,
0.6064453125,
-0.248046875,
-0.2430419921875,
-0.387939453125,
0.1968994140625,
0.08734130859375,
0.1641845703125,
0.49462890625,
-0.51318359375,
-0.00439453125,
0.0147705078125,
-0.1605224609375,
0.272216796875,
-0.126708984375,
... | 33 |
Please summerize the given abstract to a title
Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective
Coronavirus disease of 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading rapidly the world over. The disease was declared “pandemic” by the World Health Organization. An approved therapy for patients with COVID-19 has yet to emerge; however, there are some medications used in the treatment of SARS-CoV-2 infection globally including hydroxychloroquine, remdesivir, dexamethasone, protease inhibitors, and anti-inflammatory agents. Patients with underlying cardiovascular disease are at increased risk of mortality and morbidity from COVID-19. Moreover, patients with chronic stable states and even otherwise healthy individuals might sustain acute cardiovascular problems due to COVID-19 infection. This article seeks to review the latest evidence with a view to explaining possible pharmacotherapies for the cardiovascular complications of COVID-19 including acute coronary syndrome, heart failure, myocarditis, arrhythmias, and venous thromboembolism, as well as possible interactions between these medications and those currently administered (or under evaluation) in the treatment of COVID-19.
| 81,087 | [
0.0765380859375,
-0.2435302734375,
0.1397705078125,
0.72021484375,
-0.9921875,
-0.270751953125,
-0.289794921875,
0.541015625,
0.35302734375,
0.45458984375,
0.322998046875,
-0.634765625,
-0.12054443359375,
-0.7041015625,
-0.52490234375,
0.40478515625,
-0.56396484375,
-0.70458984375,... | 33 |
Please summerize the given abstract to a title
Identification and Development of Therapeutics for COVID-19
After emerging in China in late 2019, the novel Severe acute respiratory syndrome-like coronavirus 2 (SARS-CoV-2) spread worldwide and as of early 2021, continues to significantly impact most countries. Only a small number of coronaviruses are known to infect humans, and only two are associated with the severe outcomes associated with SARS-CoV-2: Severe acute respiratory syndrome-related coronavirus, a closely related species of SARS-CoV-2 that emerged in 2002, and Middle East respiratory syndrome-related coronavirus, which emerged in 2012. Both of these previous epidemics were controlled fairly rapidly through public health measures, and no vaccines or robust therapeutic interventions were identified. However, previous insights into the immune response to coronaviruses gained during the outbreaks of severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) have proved beneficial to identifying approaches to the treatment and prophylaxis of novel coronavirus disease 2019 (COVID-19). A number of potential therapeutics against SARS-CoV-2 and the resultant COVID-19 illness were rapidly identified, leading to a large number of clinical trials investigating a variety of possible therapeutic approaches being initiated early on in the pandemic. As a result, a small number of therapeutics have already been authorized by regulatory agencies such as the Food and Drug Administration (FDA) in the United States, and many other therapeutics remain under investigation. Here, we describe a range of approaches for the treatment of COVID-19, along with their proposed mechanisms of action and the current status of clinical investigation into each candidate. The status of these investigations will continue to evolve, and this review will be updated as progress is made.
| 81,318 | [
0.037689208984375,
-0.1634521484375,
-0.284423828125,
0.34326171875,
-0.7802734375,
0.1922607421875,
-0.67529296875,
0.3203125,
0.3681640625,
0.352294921875,
0.215087890625,
-0.218505859375,
-0.459716796875,
-0.83154296875,
-0.464599609375,
0.228759765625,
-0.251220703125,
-0.11486... | 33 |
Please summerize the given abstract to a title
SARS-CoV-2: From the pathogenesis to potential anti-viral treatments
INTRODUCTION: The world is witnessing the spread of one of the members of Coronaviruses (CoVs) family, called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the 21st century. Considering the short time spent after its prevalence, limited information is known about the effect of the virus mechanism on different organs of the body; meanwhile the lack of specific treatment and vaccine for this virus has exposed millions of people to a big challenge. AREAS COVERED: The review article aims to describe the general and particular characteristics of CoVs, their classification, genome structure, host cell infection, cytokine storm, anti-viral treatments, and inhibition of COVID-19-related ER-mitochondrial stress. In addition, it refers to drugs such as Chloroquine/Hydroxychloroquine, Lopinavir/Ritonavir, darunavir, ribavirin, remdesivir, and favipiravir, which have undergone clinical trials for coronavirus disease 2019 (COVID-19) treatment. This analysis was derived from an extensive scientific literature search including Pubmed, ScienceDirect, and Google Scholar performed. EXPERT OPINION: The effectiveness rate and complications of these drugs can reveal new insights into the potential therapeutic goals for the disease. Moreover, lifestyle change can effectively prevent SARS-CoV-2 infection.
| 81,360 | [
0.3212890625,
-0.1644287109375,
-0.1676025390625,
0.5126953125,
-0.88037109375,
0.2320556640625,
-0.45751953125,
0.65234375,
0.404296875,
0.339111328125,
0.49169921875,
-0.218017578125,
0.07080078125,
-0.3447265625,
-0.306640625,
0.2822265625,
-0.223876953125,
-0.37744140625,
0.1... | 33 |
Please summerize the given abstract to a title
Effective Immune Functions of Micronutrients against SARS-CoV-2
The third coronavirus outbreak in the last two decades has caused significant damage to the world's economy and community health. The highly contagious COVID-19 infection has affected millions of people to date and has led to hundreds of thousands of deaths worldwide. Aside from the highly infectious nature of SARS-CoV-2, the lack of a treatment or vaccine has been the main reason for its spread. Thus, it has become necessary to find alternative methods for controlling SARS-CoV-2. For the present review, we conducted an online search for different available nutrition-based therapies for previously known coronavirus infections and RNA-based virus infections as well as general antiviral therapies. These treatments have promise for combating COVID-19, as various nutrients and minerals play direct and indirect roles in the control and prevention of this newly emerged viral infection. The patients' nutritional status with COVID-19 must be analyzed before administering any treatment, and nutritional supplements should be given to the affected individuals along with routine treatment. We suggest a potential interventional role of nutrients to strengthen the immune system against the emerging infection caused by COVID-19.
| 81,431 | [
0.1290283203125,
-0.1793212890625,
-0.0082244873046875,
0.71875,
-0.880859375,
0.12841796875,
-0.1124267578125,
0.49169921875,
0.19287109375,
0.6494140625,
0.11810302734375,
-0.3173828125,
0.1064453125,
-0.69775390625,
-0.42333984375,
-0.260009765625,
-0.26708984375,
-0.65673828125... | 33 |
Please summerize the given abstract to a title
Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments.
The coronavirus disease emerged in December 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome-related coronavirus 2 (SARS-CoV-2) and its rapid global spread has brought an international health emergency and urgent responses for seeking efficient prevention and therapeutic treatment. This has led to imperative needs for illustration of the molecular pathogenesis of SARS-CoV-2, identification of molecular targets or receptors, and development of antiviral drugs, antibodies, and vaccines. In this study, we investigated the current research progress in combating SARS-CoV-2 infection. Based on the published research findings, we first elucidated, at the molecular level, SARS-CoV-2 viral structures, potential viral host-cell-invasion and pathogenic mechanisms, main virus-induced immune responses, and emerging SARS-CoV-2 variants. We then focused on the main virus- and host-based potential targets, summarized and categorized effective inhibitory molecules based on drug development strategies for COVID-19, that can guide efforts for the identification of new drugs and treatment for this problematic disease. Current research and development of antibodies and vaccines were also introduced and discussed. We concluded that the main virus entry route- SARS-CoV-2 spike protein interaction with ACE2 receptors has played a key role in guiding the development of therapeutic treatments against COVID-19, four main therapeutic strategies may be considered in developing molecular therapeutics, and drug repurposing is likely to be an easy, fast and low-cost approach in such a short period of time with urgent need of antiviral drugs. Additionally, the quick development of antibody and vaccine candidates has yielded promising results, but the wide-scale deployment of safe and effective COVID-19 vaccines remains paramount in solving the pandemic crisis. As new variants of the virus begun to emerge, the efficacy of these vaccines and treatments must be closely evaluated. Finally, we discussed the possible challenges of developing molecular therapeutics for COVID-19 and suggested some potential future efforts. Despite the limited availability of literatures, our attempt in this work to provide a relatively comprehensive overview of current SARS-CoV-2 studies can be helpful for quickly acquiring the key information of COVID-19 and further promoting this important research to control and diminish the pandemic.
| 81,469 | [
-0.0187835693359375,
0.038421630859375,
0.04705810546875,
0.23486328125,
-0.54541015625,
-0.11572265625,
-0.439208984375,
0.42431640625,
0.022064208984375,
0.261474609375,
0.0171661376953125,
-0.345947265625,
-0.311279296875,
-0.68115234375,
-0.350830078125,
0.07061767578125,
-0.2369... | 33 |
Please summerize the given abstract to a title
Current Paradigms in COVID-19 Research: Proposed Treatment Strategies, Recent Trends and Future Directions
BACKGROUND: Recent pandemic of coronavirus disease caused by a novel coronavirus SARS-CoV-2 in humans is the third outbreak by this family of viruses leading to an acute respiratory infection which has been a major cause of morbidity and mortality worldwide.The virus belongs to the genus, Betacoronavirus which has been recently reported to have significant similarity (>89%) to a severe acute respiratory syndrome (SARS)-related member of the Sarbecoviruses. Current researches are not sufficient to understand the etiological and immunopathobiological parameters related to COVID-19 so as to have a therapeutic solution to the problem. METHODS: A structured search of bibliographic databases for peer-reviewed research literature has been carried out using focused review questions and inclusion/exclusion criteria. Further Standard tools were implied in order to appraise the quality of retrieved papers. The characteristic outcomes of screened research and review articles along with analysis of the interventions and findings of included studies using a conceptual framework have been described employing a deductive qualitative content analysis methodology. RESULTS: This review systematically summarizes the immune-pathobiological characteristics, diagnosis, potential therapeutic options for the treatment and prevention of COVID-19 based on the current published literature and evidence. The current review has covered 125 peer-reviewed articles, majority of which are from high-income technically developed countries providing the most recent updates about the current understanding of the COVID-19 bringing all the significant findings and related researches together at a single platform. In addition, possible therapeutic interventions, treatment strategies and vaccine development initiatives to manage COVID-19 have been proposed. CONCLUSIONS: It is anticipated that this review would certainly assist the public in general and scientific community in particular to recognize and effectively deal with COVID-19, providing a reference guide for futuristic studies.
| 81,481 | [
0.2056884765625,
-0.26708984375,
-0.5126953125,
0.5751953125,
-0.29541015625,
0.08172607421875,
-0.1754150390625,
0.2132568359375,
0.3125,
0.4658203125,
0.28173828125,
-0.399169921875,
-0.185302734375,
-0.42138671875,
-0.10638427734375,
-0.411376953125,
-0.1585693359375,
-0.7817382... | 33 |
Please summerize the given abstract to a title
Statins: Could an old friend help in the fight against COVID-19?
The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has overwhelmed healthcare systems requiring the rapid development of treatments, at least, to reduce COVID-19 severity. Drug repurposing offers a fast track. Here, we discuss the potential beneficial effects of statins in COVID-19 patients based on evidence that they may target virus receptors, replication, degradation, and downstream responses in infected cells, addressing both basic research and epidemiological information. Briefly, statins could modulate virus entry, acting on the SARS-CoV-2 receptors, ACE2 and CD147, and/or lipid rafts engagement. Statins, by inducing autophagy activation, could regulate virus replication or degradation, exerting protective effects. The well-known anti-inflammatory properties of statins, by blocking several molecular mechanisms, including NF-κB and NLRP3 inflammasomes, could limit the "cytokine storm" in severe COVID-19 patients which is linked to fatal outcome. Finally, statin moderation of coagulation response activation may also contribute to improving COVID-19 outcomes. LINKED ARTICLES: This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc.
| 81,528 | [
0.4775390625,
-0.05352783203125,
0.204833984375,
0.7392578125,
-0.38818359375,
0.10272216796875,
-0.272216796875,
0.59033203125,
-0.037322998046875,
0.67431640625,
0.26953125,
-0.57763671875,
0.082763671875,
-0.35498046875,
-0.411376953125,
0.384521484375,
-0.1658935546875,
-0.5185... | 33 |
Please summerize the given abstract to a title
Role of 2-Deoxy-D-Glucose (2-DG) in COVID-19 disease: A potential game-changer
Virus infections can cause tissue damage in many ways. Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a cause of the current COVID-19 pandemic, has been extensively studied so far to investigate its pathophysiology and evaluate its impact on the metabolic system of human cells. This has given a lead to study the role of 2-deoxy-D-glucose (2DG) against COVID-19 disease. We hereby would like to briefly discuss the concept and rationale behind the use of 2DG COVID-19.
| 81,631 | [
0.181396484375,
-0.144287109375,
0.1846923828125,
1.0107421875,
-0.8203125,
-0.401611328125,
0.2364501953125,
0.40478515625,
0.088134765625,
0.398193359375,
0.39697265625,
-0.75927734375,
0.409423828125,
-0.385009765625,
-0.28515625,
0.24853515625,
-0.039337158203125,
-0.4289550781... | 33 |
Please summerize the given abstract to a title
A review on favipiravir: the properties, function, and usefulness to treat COVID-19.
INTRODUCTION At this time, there is no specific therapeutic or vaccine for treatment of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Hence, available drugs for treatment of other viral infections may be useful to treat COVID-19. AREAS COVERED The focus of the current review was studying the main characteristics of favipiravir and its usefulness to treat COVID-19. An electronic search was done by using Pubmed and Google scholar. EXPERT OPINION Based on the mechanism of action and safety of favipiravir, the drug may be a promising candidate for compassionate use against the SARS-CoV-2 infection. Favipiravir has a wide range of activity against many single-stranded RNA viruses, is well tolerated in humans and has a high barrier to resistance. However, high doses of the agent are necessary to obtain an efficient antiviral activity. Favipiravir is teratogen in pregnant women and associated with the hyperuricemia. Therefore, the administration of the drug should be well controlled. Investigating the antiviral prophylactic potency of favipiravir and search for its pro-drugs and/or analogs showing improved activity and/or safety are critical.
| 81,783 | [
0.1112060546875,
-0.2459716796875,
-0.062408447265625,
0.350341796875,
-0.98779296875,
-0.183837890625,
-0.1678466796875,
0.489013671875,
0.31591796875,
0.52197265625,
0.328857421875,
-0.54150390625,
0.1673583984375,
-0.4541015625,
0.07696533203125,
0.348388671875,
-0.1444091796875,
... | 33 |
Please summerize the given abstract to a title
Pharmacologicaltreatment of COVID-19: lights and shadows
At the end of December 2019, a novel coronavirus, the severe acute respiratory syndrome coronavirus 2, caused an outbreak of pneumonia spreading from Wuhan, Hubei province, to the whole country of China and then the entire world, forcing the World Health Organization to make the assessment that the coronavirus disease (COVID-19) can be characterized as a pandemic, the first ever caused by a coronavirus To date, clinical evidence and guidelines based on reliable data and randomized clinical trials for the treatment of COVID-19 are lacking In the absence of definitive management protocols, many treatments for COVID-19 are currently being evaluated and tested worldwide Some of these options were soon abandoned due to ineffectiveness, while others showed promising results The basic treatments are mainly represented by antiviral drugs, even if the evidence is not satisfactory Among the antivirals, the most promising appears to be remdesivir Corticosteroids and tocilizumab seem to guarantee positive results in selected patients so far, although the timing of starting therapy and the most appropriate therapeutic schemes remain to be clarified Efficacy of the other drugs is still uncertain, and they are currently used as a cocktail of treatments in the absence of definitive guidelines What will represent the real solution to the enormous problem taking place worldwide is the identification of a safe and effective vaccine, for which enormous efforts and investments are underway
| 81,820 | [
0.04119873046875,
-0.59326171875,
-0.2117919921875,
0.439208984375,
-0.74755859375,
-0.56787109375,
-0.2066650390625,
0.66845703125,
0.21630859375,
0.74853515625,
0.295654296875,
-0.54443359375,
-0.10791015625,
-0.49267578125,
-0.6611328125,
0.47998046875,
-0.7607421875,
-0.4450683... | 33 |
Please summerize the given abstract to a title
Understanding the dynamics of COVID-19; implications for therapeutic intervention, vaccine development and movement control
The COVID-19 disease is caused by the recently identified SARS-CoV-2 virus, thought to have originated in bats (Rhinolophus affinis), the virus being highly infective within the human population and spread by respiratory droplets, contaminated surfaces and close person-to-person contact. The virus is now pandemic and widely disseminated to almost every continent and nation with globally over twenty-seven million infections and over ninety-thousand reported deaths attributed to the COVID-19 disease. SARS-CoV-2 is a single stranded RNA virus, similar in structure to that of other coronaviruses and comprising three main viral proteins; membrane (M), spike (S) and envelope (E). The clinical features of COVID-19 disease can be classified according to different degrees of severity, with some patients, particularly those of older age and with long-standing chronic illnesses, developing progressive respiratory failure and acute respiratory distress syndrome requiring mechanical ventilation. In these severe cases, the disease can frequently be fatal. In addition, many infections are asymptomatic or only cause mild symptoms. As there is no specific treatment for COVID-19 there is considerable scientific endeavor globally to raise a safe and effective vaccine against SARS-CoV-2, in addition to engineering neutralizing antibody interventions. In the absence of an effective vaccine, interim measures involving movement control and lock downs of varying stringencies have been imposed, in order to control the spread of the virus. Whilst early enforced lockdown measures have been effective in reducing the spread of infection, these measures may prove to be less effective against the current and predominant strain of SARS-CoV-2, the G614 clade. Conversely, other mutations of the virus, such as the Δ382 variant could reduce the clinical relevance of infection, and therefore may reduce the need for stringent movement control, particularly once vaccines become widely available. The front runners in the race to develop an effective vaccine focus on the SARS-Co-V-2 Spike protein. However, vaccines that produce a CD4 and CD8 response to a wider range of SARS-Co-V-2 viral proteins, may be more effective. Lastly, population based studies that determine the level of innate immunity to SARS-CoV-2 existing in the community, from prior exposure to the virus or to other coronaviruses, will have important implications for the stringencies of government imposed movement control and upon the strategic delivery of vaccination programmes.
| 81,880 | [
0.2266845703125,
0.086181640625,
-0.1256103515625,
0.54931640625,
-0.374755859375,
-0.1258544921875,
-0.36767578125,
0.52197265625,
-0.061126708984375,
0.560546875,
0.09478759765625,
-0.2427978515625,
-0.2244873046875,
-0.452880859375,
-0.283935546875,
0.25927734375,
-0.333984375,
... | 33 |
Please summerize the given abstract to a title
Applications of Artificial Intelligence in Battling Against Covid-19: A Literature Review
Colloquially known as coronavirus, the Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2), that causes CoronaVirus Disease 2019 (COVID-19), has become a matter of grave concern for every country around the world. The rapid growth of the pandemic has wreaked havoc and prompted the need for immediate reactions to curb the effects. To manage the problems, many research in a variety of area of science have started studying the issue. Artificial Intelligence is among the area of science that has found great applications in tackling the problem in many aspects. Here, we perform an overview on the applications of AI in a variety of fields including diagnosis of the disease via different types of tests and symptoms, monitoring patients, identifying severity of a patient, processing covid-19 related imaging tests, epidemiology, pharmaceutical studies, etc. The aim of this paper is to perform a comprehensive survey on the applications of AI in battling against the difficulties the outbreak has caused. Thus we cover every way that AI approaches have been employed and to cover all the research until the writing of this paper. We try organize the works in a way that overall picture is comprehensible. Such a picture, although full of details, is very helpful in understand where AI sits in current pandemonium. We also tried to conclude the paper with ideas on how the problems can be tackled in a better way and provide some suggestions for future works.
| 81,889 | [
0.1920166015625,
0.033935546875,
-0.039764404296875,
0.2452392578125,
-0.68212890625,
-0.311767578125,
-0.309814453125,
0.322998046875,
0.30322265625,
0.84619140625,
0.205322265625,
-0.52490234375,
-0.1871337890625,
-0.66748046875,
-0.3857421875,
-0.1881103515625,
-0.290771484375,
... | 33 |
Please summerize the given abstract to a title
Practical Recommendations Relevant to the Use of Resistance Training for COVID-19 Survivors
The novel coronavirus disease (COVID-19) has emerged at the end of 2019 and caused a global pandemic. The disease predominantly affects the respiratory system; however, there is evidence that it is a multisystem disease that also impacts the cardiovascular system. Although the long-term consequences of COVID-19 are not well-known, evidence from similar diseases alerts for the possibility of long-term impaired physical function and reduced quality of life, especially in those requiring critical care. Therefore, rehabilitation strategies are needed to improve outcomes in COVID-19 survivors. Among the possible strategies, resistance training (RT) might be particularly interesting, since it has been shown to increase functional capacity both in acute and chronic respiratory conditions and in cardiac patients. The present article aims to propose evidence-based and practical suggestions for RT prescription for people who have been diagnosed with COVID-19 with a special focus on immune, respiratory, and cardiovascular systems. Based on the current literature, we present RT as a possible safe and feasible activity that can be time-efficient and easy to be implemented in different settings.
| 81,941 | [
0.1676025390625,
0.191650390625,
-0.50390625,
0.5498046875,
-0.6005859375,
-0.3125,
-0.2291259765625,
0.447509765625,
0.0970458984375,
0.71923828125,
0.3740234375,
-0.3876953125,
-0.09490966796875,
-0.478759765625,
-0.376220703125,
0.2191162109375,
-0.401611328125,
-0.68798828125,
... | 33 |
Please summerize the given abstract to a title
Treatment considerations for Behçet disease in the era of COVID-19: A narrative review
COVID-19 is a multisystem disease caused by severe acute respiratory syndrome coronavirus 2. It has been declared a pandemic by the World Health Organization in March 2020 and the outbreak still keeps its impacts worldwide. Behçet disease (BD) is a multi-systemic vasculitis involving the skin, mucosa, eyes, joints, nervous system, cardiovascular system, and gastrointestinal system. The precise etiopathogenesis of the disorder is unknown but autoimmunity is believed to play a key role. A considerable part of patients with BD are susceptible to immunosuppression and are more predisposed to infections than healthy individuals. Hence, the protection and control measures for patients with BD against the COVID-19 are of the utmost significance. Given the requirement to balance proper treatment of BD with the smallest risk of COVID-19 associated mortality and morbidity, we aimed to review the management of BD in the era of the pandemic with a special focus on treatment considerations. According to current expert recommendations, there is no reason to discontinue topical treatments, colchicine, and nonsteroidal antiinflammatory drugs. Systemic steroids can be used at the lowest possible dose if needed. Ongoing treatments can be continued unchanged in patients with no suspected or confirmed COVID-19. In cases with COVID-19 symptoms, immunosuppressive and biological agents can be temporarily stopped but the decision should be made on a case by case basis. Considering their potential beneficial effects on the course of COVID-19, colchicine, pentoxifylline, and dapsone can be considered as safe treatment options in BD.
| 82,004 | [
0.1285400390625,
-0.2216796875,
-0.062042236328125,
0.60986328125,
-0.826171875,
-0.30712890625,
0.07080078125,
0.291259765625,
0.378173828125,
0.0244903564453125,
0.478759765625,
-0.82275390625,
0.0450439453125,
-0.37646484375,
-0.75244140625,
0.23095703125,
-1.1162109375,
-0.8198... | 33 |
Please summerize the given abstract to a title
Combinatorial therapeutic trial plans for COVID-19 treatment armed up with antiviral, antiparasitic, cell-entry inhibitor, and immune-boosters
SARS-CoV-2, or novel coronavirus, is causing the fatal and contagious coronavirus disease-2019 (COVID-19) affecting thousands of people every single day. Researchers are continuously searching for any possible cure and/or vaccine, but no conclusive report is available till date. Like many others, we realize that a rapid, immediate, and elaborate strategy must be adopted to protect mankind. To avoid the time-loss due to clinical trials, we have performed in silico analyses on some FDA-approved drugs to combat COVID-19. We accessed information from public databases and publications, and studied the mechanism of infection of SARS-CoV-2 and the interactions of various drugs with SARS-CoV-2 proteins in silico. We found a few antivirals and antiparasitic drugs to show significant interactions with important SARS-CoV-2 proteins. Particularly Galidesivir, Remdesivir, and Pirodavir have been chosen as suggested antiviral drugs; and Proguanil, Mefloquine, and Artesunate have been chosen as suggested antiparasitic drugs based on such predicted interactions. In addition, inhibitors to prevent host-cell entry and a few supportive immune-boosters can be used in different combinations. Our study proposes a four-way attack to this fatal virus for the possible management of COVID-19 armed up with an antiviral, an antiparasitic drug, a cell-entry inhibitor, and a few supportive immune-boosters, which can be used in different combinations in different groups of people.
| 82,134 | [
0.10626220703125,
-0.11297607421875,
0.2393798828125,
0.40576171875,
-0.416259765625,
-0.2744140625,
-0.3515625,
0.94580078125,
0.1728515625,
0.7568359375,
0.253662109375,
-0.285400390625,
0.25634765625,
-0.54345703125,
-0.387939453125,
0.357666015625,
-0.302978515625,
-0.680175781... | 33 |
Please summerize the given abstract to a title
[SARS-CoV-2 infection: Available data on 15th April 2021]./ Infection à SARS-CoV-2 : connaissances au 15 avril 2021
INTRODUCTION: Since January 2020, when the first cases of SARS-CoV-2 infection were diagnosed in France, pulmonologists have been at the heart of the crisis and should be responsible for the management of acute COVID-19 (and any possible sequelae) BACKGROUND: Many drugs have been evaluated or are currently under evaluation as possible specific treatment for SARS-CoV-2. Nevertheless, as of April 15, 2021, the only recommended treatment in current practice is the "standard of care", i.e. the symptomatic management of infection with SARS-CoV-2. This review presents the state of knowledge on COVID-19 in the acute phase (virological, immunological, epidemiological and therapeutic data) available on 15th April, 2021. OUTLOOK: A large number of clinical trials are currently ongoing. It is important to propose to patients the opportunity to participate in clinical trials and to structure the research in order to complete the studies. CONCLUSION: Current management is based on oxygen therapy, thromboprophylaxis and in some cases corticosteroids. No antiviral therapy is currently recommended. These data are constantly evolving.
| 82,148 | [
0.3349609375,
0.1798095703125,
-0.5439453125,
0.26318359375,
-0.82861328125,
-0.03070068359375,
-0.1435546875,
0.327880859375,
0.82470703125,
0.64892578125,
0.07940673828125,
-0.5654296875,
0.1268310546875,
-0.4814453125,
-0.483642578125,
0.42626953125,
-0.4365234375,
-0.86328125,
... | 33 |
Please summerize the given abstract to a title
A proposed insight into the anti-viral potential of metallic nanoparticles against novel coronavirus disease-19 (COVID-19)
Background: Over the last ten months since December 2019, the world has faced infectious emerging novel coronavirus disease-2019 (COVID-19) outbreaks that had a massive global impact affecting over 185 countries Main body: Emerging novel COVID-19 is a global health emergency on a pandemic scale that represents a terror to human health through its ability to escape anti-viral measures Such viral infections impose a great socioeconomic burden, besides global health challenges This imposes a pressing need for the development of anti-viral therapeutic agents and diagnostic tools that demonstrate multifunctional, target-specific, and non-toxic properties Nanotheranostics is regarded as a promising approach for the management of different viral infections Nanotheranostics facilitates targeted drug-delivery of anti-viral therapeutics as well as contributing to the development of diagnostic systems Multifunctional metallic nanoparticles (NPs) have emerged as innovative theranostic agents that enable sustainable treatment and effective diagnosis Here we have reviewed current advances in the use of theranostic metallic NPs to fight against COVID-19, and discussed the application as well as limitations associated with nanotechnology-based theranostic approaches Conclusion: This review verified the potential use of some metal-based NPs as anti-viral nanotheranostic agents Metal-based NPs could act as carriers that enable the sustainable and targeted delivery of active anti-viral molecules, or as diagnostic agents that allow rapid and sensitive diagnosis of viral infections
| 82,158 | [
0.212158203125,
-0.5546875,
-0.54052734375,
0.52392578125,
-0.396728515625,
-0.04266357421875,
-0.485107421875,
0.52294921875,
0.3515625,
0.5537109375,
0.445556640625,
-0.548828125,
0.116943359375,
-0.193603515625,
-0.475341796875,
0.55224609375,
-0.399658203125,
-1.02734375,
-0.... | 33 |
Please summerize the given abstract to a title
Hospital Course of a Man With Viral Pneumonia Caused by COVID-19
The authors present a case of a man with pneumonia caused by COVID-19. There is currently no FDA-approved medical treatment or vaccine for COVID-19, so a variety of drugs and medicinal therapies have been repurposed for use in hospital settings and clinical studies while the medical community waits for a medication to be approved and standardized. Pneumonia is a common outcome of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), so cases of it are rapidly spreading around the world as the novel coronavirus continues to spread.
| 82,212 | [
0.28515625,
-0.55517578125,
-0.388671875,
0.81982421875,
-0.44873046875,
-0.1568603515625,
-0.40673828125,
0.38427734375,
0.0120086669921875,
0.77783203125,
0.72119140625,
-0.292236328125,
0.466552734375,
-0.7578125,
-0.6591796875,
0.5048828125,
-0.4736328125,
-1.1845703125,
-0.1... | 33 |
Please summerize the given abstract to a title
Chinese herbal injections for Coronavirus Disease 2019 (COVID-19): A narrative review
BACKGROUND: The outbreak of Coronavirus disease 2019 (COVID-19) has caused more than 180 million infections and 3.9 million deaths. To date, emerging clinical evidence has shown the synergetic benefits of Chinese herbal injections in treating this contagious respiratory disease. This review aims to summarize and analyze the efficacy and safety of Chinese herbal injections in the therapy of COVID-19. METHODS: The literature from 3 electronic databases, PubMed, CNKI, and Web of Science, were searched using the search terms “COVID-19”, “SARS-CoV-2”, “traditional Chinese medicine”, “herb”, “herbal”, and “injection”. Then the identified articles were comprehensively evaluated. RESULTS: Limited data demonstrated that Chinese herbal injections could significantly improve the clinical outcomes of COVID-19 patients, especially in combination with conventional treatment strategies. The benefits of which were mainly associated with the relief of symptoms, prevention of secondary infection, regulation of inflammation and immune function. There was also evidence showing the inhibitory effects on SARS-CoV-2 replication in vitro. Nevertheless, available real-world data suggested the increased risk of adverse event. Furthermore, the defects of existing researches and the insights for discovering novel antiviral drugs were prospectively discussed. CONCLUSION: Evidence-based advances revealed that Chinese herbal injections such as XueBiJing injection and ShenMai injection, exerted potent effects against COVID-19. Further laboratory researches and clinical evaluation are needed to gather scientific evidence on the efficacy and safety.
| 82,602 | [
-0.304443359375,
-0.436767578125,
0.041229248046875,
0.406005859375,
-0.1927490234375,
0.00787353515625,
-0.233642578125,
0.6748046875,
0.261962890625,
0.78173828125,
0.336181640625,
0.0831298828125,
0.1634521484375,
-0.45654296875,
-0.1485595703125,
0.213623046875,
0.033477783203125... | 33 |
Please summerize the given abstract to a title
COVID-19: Guidelines for pharmacists in South Africa
Epidemiology. The virus, its modes of transmission and incubation period. Symptom identification, including the differentiation between influenza, allergic rhinitis, sinusitis and COVID-19. Social media myths and misinformation. Treatment guidelines and medicines that may need to be kept in stock. Treatment and prevention options, including an update on vaccine development. The case for and against the use of NSAIDs, ACE-inhibitors and angiotensin receptor blockers (ARBs) in patients with COVID-19. Interventions and patient counselling by the pharmacist. World Health Organization (WHO): https://www.who.int/emergencies/diseases/novel-coronavirus-2019. National Institute for Communicable Diseases (NICD): https://www.nicd.ac.za/diseases-a-z-index/covid-19/. National Department of Health (NDoH): http://www.health.gov.za/index.php/outbreaks/145-corona-virus-outbreak/465-corona-virus-outbreak; https://sacoronavirus.co.za/;
| 82,679 | [
0.06439208984375,
-0.211181640625,
-0.51171875,
0.58154296875,
-0.170166015625,
-0.364013671875,
-0.07098388671875,
0.276611328125,
0.291259765625,
1.0419921875,
0.560546875,
-0.3935546875,
0.1279296875,
-0.59716796875,
-0.060028076171875,
0.1392822265625,
-0.662109375,
-0.55908203... | 33 |
Please summerize the given abstract to a title
The COVID-19 Ontology
MOTIVATION: The COVID-19 pandemic has prompted an impressive, worldwide response by the academic community. In order to support text mining approaches as well as data description, linking and harmonization in the context of COVID-19, we have developed an ontology representing major novel coronavirus (SARS-CoV-2) entities. The ontology has a strong scope on chemical entities suited for drug repurposing, as this is a major target of ongoing COVID-19 therapeutic development. RESULTS: The ontology comprises 2.270 classes of concepts and 38.987 axioms (2622 logical axioms and 2434 declaration axioms). It depicts the roles of molecular and cellular entities in virus-host interactions and in the virus life cycle, as well as a wide spectrum of medical and epidemiological concepts linked to COVID-19. The performance of the ontology has been tested on Medline and the COVID-19 corpus provided by the Allen Institute. AVAILABILITY: COVID-19 Ontology is released under a Creative Commons 4.0 License and shared via https://github.com/covid-19-ontology/covid-19. The ontology is also deposited in BioPortal at https://bioportal.bioontology.org/ontologies/COVID-19.
| 82,893 | [
0.0682373046875,
-0.6435546875,
-0.2490234375,
0.2171630859375,
0.034576416015625,
-0.154296875,
0.0006060600280761719,
0.048614501953125,
0.07220458984375,
0.38037109375,
0.6396484375,
-0.90673828125,
0.1329345703125,
-0.57763671875,
-0.0986328125,
0.489990234375,
-0.320556640625,
... | 33 |
Please summerize the given abstract to a title
Fighting against the second wave of COVID-19: Can honeybee products help protect against the pandemic?
Coronavirus Disease (COVID-19) has infected people in 210 nations and has been declared a pandemic on March 12, 2020 by the World Health Organization (WHO). In the absence of effective treatment and/or vaccines for COVID-19, natural products of known therapeutic and antiviral activity could offer an inexpensive, effective option for managing the disease. Benefits of products of honey bees such as honey, propolis, and bee venom, against various types of diseases have been observed. Honey bees products are well known for their nutritional and medicinal values, they have been employed for ages for various therapeutic purposes. In this review, promising effects of various bee products against the emerging pandemic COVID-19 are discussed. Products of honey bees that contain mixtures of potentially active chemicals, possess unique properties that might help to protect, fight, and alleviate symptoms of COVID-19 infection.
| 82,997 | [
0.1365966796875,
-0.2442626953125,
-0.3623046875,
0.271484375,
-0.57958984375,
0.00614166259765625,
-0.28271484375,
0.78662109375,
0.498291015625,
0.2000732421875,
0.2200927734375,
-0.3349609375,
-0.243896484375,
-0.68994140625,
-0.52001953125,
0.23974609375,
-0.238525390625,
-0.94... | 33 |
Please summerize the given abstract to a title
Medication Rule Analysis of the Diagnosis and Treatment Programs of Chinese Medicine for the Prevention and Treatment of COVID-19 in China
OBJECTIVES: To summarize the measures and rules of Chinese medicine (CM) and provide reference for clinical application in the prevention and treatment of coronavirus disease (COVID-19). METHODS: The data source was from CM COVID-19 prevention and treatment programs on government websites and official media websites of the different provinces and cities. The search lasted from December 8, 2019 to March 10, 2020. Main variables were medication frequency and combinations of medicines. Cluster analysis and complex network analysis were used by prevention and treatment stage and by area. RESULTS: Among 27 CM diagnosis and treatment plans, 203 therapeutic prescriptions were enrolled, of which the top 4 herbs were: Radix glycyrrhizae, Semen armeniacae amarum, Herba ephedrae, and Herba agastachis, respectively. The core combinations were Herba ephedrae and Semen armeniacae amarum. Forty-eight preventive formulae were identified. Ten herbs, including Radix Astragali seu hedysari, Radix glycyrrhizae, Radix saposhnikoviae, Flos lonicerae, etc. were most frequently used. The core prescription of CM compatibility was Radix astragali seu hedysari, Radix glycyrrhizae, and Radix saposhnikoviae, which is the main component of Yu Ping Feng San. There were 45 prevention and treatment prescriptions in East China; the most used CM was Radix glycyrrhizae, Herba agastachis, Pericarpium citri reticulatae, and Gypsum fibrosum. Fifty prescriptions were identified in North China. According to CM analyses, Herba agastachis, Semen armeniacae amarum, Herba ephedrae, and Poria were most frequently used. CONCLUSIONS: CM for COVID-19 prevention mainly focuses on improving human immunity; for treatment, prescription focuses on clearing the lungs and removing dampness. Prescriptions vary with regions, perhaps due to climatic and environmental differences, which help clinicians to quickly make CM plans and treat patients according to clinical status, further minimizing resource wastage. ELECTRONIC SUPPLEMENTARY MATERIAL: Supplementary materials (Appendices) are available in the online version of this article at 10.1007/s11655-021-2880-1
| 83,059 | [
-0.102294921875,
-0.330078125,
0.25634765625,
0.59521484375,
-0.6337890625,
-0.6513671875,
0.2452392578125,
0.42431640625,
0.57080078125,
0.424072265625,
0.70703125,
-0.57373046875,
0.215576171875,
-0.69775390625,
-0.59619140625,
-0.01515960693359375,
-0.6630859375,
-0.9033203125,
... | 33 |
Please summerize the given abstract to a title
The time to offer treatments for COVID-19
Background: COVID-19 has several overlapping phases. Treatments to date have focused on the late stage of disease in hospital. Yet, the pandemic is by propagated by the viral phase in out-patients. The current public health strategy relies solely on vaccines to prevent disease.Methods: We searched the major national registries, pubmed.org, and the preprint servers for all ongoing, completed and published trial results.Results: As of 2/15/2021, we found 111 publications reporting findings on 14 classes of agents, and 9 vaccines. There were 62 randomized controlled studies, the rest retrospective observational analyses. Only 21 publications dealt with outpatient care. Remdesivir and high titer convalescent plasma have emergency use authorization for hospitalized patients in the U.S.A. There is also support for glucocorticoid treatment of the COVID-19 respiratory distress syndrome. Monoclonal antibodies are authorized for outpatients, but supply is inadequate to treat all at time of diagnosis. Favipiravir, ivermectin, and interferons are approved in certain countries.Expert Opinion: Vaccines and antibodies are highly antigen specific, and new SARS-Cov-2 variants are appearing. We call on public health authorities to authorize treatments with known low-risk and possible benefit for outpatients in parallel with universal vaccination.
| 83,101 | [
0.392578125,
-0.487548828125,
-0.4775390625,
0.544921875,
-0.28564453125,
-0.285400390625,
-0.2744140625,
0.442138671875,
0.2379150390625,
0.405029296875,
0.322998046875,
-0.391357421875,
0.31787109375,
-0.454833984375,
-0.5556640625,
0.587890625,
-0.67431640625,
-0.53271484375,
... | 33 |
Please summerize the given abstract to a title
Functionalized Dendrimer Platforms as a New Forefront Arsenal Targeting SARS-CoV-2: An Opportunity
The novel human coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) has caused a pandemic. There are currently several marketed vaccines and many in clinical trials targeting SARS-CoV-2. Another strategy is to repurpose approved drugs to decrease the burden of the COVID-19 (official name for the coronavirus disease) pandemic. as the FDA (U.S. Food and Drug Administration) approved antiviral drugs and anti-inflammatory drugs to arrest the cytokine storm, inducing the production of pro-inflammatory cytokines. Another view to solve these unprecedented challenges is to analyze the diverse nanotechnological approaches which are able to improve the COVID-19 pandemic. In this original minireview, as promising candidates we analyze the opportunity to develop biocompatible dendrimers as drugs themselves or as nanocarriers against COVID-19 disease. From the standpoint of COVID-19, we suggest developing dendrimers as shields against COVID-19 infection based on their capacity to be incorporated in several environments outside the patients and as important means to stop transmission of SARS-CoV-2.
| 83,103 | [
-0.057647705078125,
-0.2335205078125,
0.00537872314453125,
0.80810546875,
-0.52783203125,
-0.07403564453125,
-0.91845703125,
0.281005859375,
0.1207275390625,
0.1993408203125,
0.2296142578125,
-0.73876953125,
0.1246337890625,
-0.451416015625,
-0.54443359375,
0.58740234375,
-0.40014648... | 33 |
Please summerize the given abstract to a title
Vagus Nerve Stimulation: A Potential Adjunct Therapy for COVID-19
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) through excessive end organ inflammation Despite improved understanding of the pathophysiology, management, and the great efforts worldwide to produce effective drugs, death rates of COVID-19 patients remain unacceptably high, and effective treatment is unfortunately lacking Pharmacological strategies aimed at modulating inflammation in COVID-19 are being evaluated worldwide Several drug therapies targeting this excessive inflammation, such as tocilizumab, an interleukin (IL)-6 inhibitor, corticosteroids, programmed cell death protein (PD)-1/PD-L1 checkpoint inhibition, cytokine-adsorption devices, and intravenous immunoglobulin have been identified as potentially useful and reliable approaches to counteract the cytokine storm However, little attention is currently paid for non-drug therapeutic strategies targeting inflammatory and immunological processes that may be useful for reducing COVID-19-induced complications and improving patient outcome Vagus nerve stimulation attenuates inflammation both in experimental models and preliminary data in human Modulating the activity of cholinergic anti-inflammatory pathways (CAPs) described by the group of KJ Tracey has indeed become an important target of therapeutic research strategies for inflammatory diseases and sepsis Non-invasive transcutaneous vagal nerve stimulation (t-VNS), as a non-pharmacological adjuvant, may help reduce the burden of COVID-19 and deserve to be investigated VNS as an adjunct therapy in COVID-19 patients should be investigated in clinical trials Two clinical trials on this topic are currently underway (NCT04382391 and NCT04368156) The results of these trials will be informative, but additional larger studies are needed
| 83,114 | [
0.0120697021484375,
0.071533203125,
-0.2232666015625,
0.61474609375,
-0.52587890625,
-0.5771484375,
-0.51708984375,
0.149169921875,
-0.341796875,
0.40478515625,
-0.266845703125,
-0.60791015625,
0.062225341796875,
-0.900390625,
-0.379150390625,
0.07318115234375,
-0.26171875,
-0.7983... | 33 |
Please summerize the given abstract to a title
Current Progress and Challenges in the Design and Development of a Successful COVID-19 Vaccine
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is still a worldwide concern, with little to no sign of a decreasing trend There is a general consensus that normal life will be hampered until a safe and effective vaccine strategy is available and globally administered Numerous countries have accelerated the clinical trials process for the development of a successful COVID-19 treatment, with over 200 candidates presently available for testing against SARS-CoV-2 Here, we provide an overview of the COVID-19 vaccine candidates currently in development, discuss the scientific and practical challenges associated with COVID-19 vaccine design, and share the potential strategies that could be exploited for vaccine design success
| 83,175 | [
0.29150390625,
-0.275634765625,
-0.740234375,
0.45703125,
-0.418701171875,
-0.27685546875,
-0.53759765625,
0.464111328125,
0.13818359375,
0.328369140625,
0.324951171875,
-0.1768798828125,
-0.1378173828125,
-0.47607421875,
-0.270263671875,
0.427734375,
-0.05548095703125,
-0.39501953... | 33 |
Please summerize the given abstract to a title
Adipose Stem Cells (ASCs) and Stromal Vascular Fraction (SVF) as a Potential Therapy in Combating (COVID-19)-Disease
A recent and interesting study reported improved respiratory activity after intravenous administration of mesenchymal stem cells (MSCs) into patients affected by coronavirus disease 2019 (COVID-19). These outcomes displayed that intravenous infiltration of MSCs is a safe and efficacy treatment for COVID-19 pneumonia, a severe acute respiratory illness caused by the coronavirus 2 (SARS-CoV-2). Only 7 patients were treated, but with extraordinary results, opening a new strategy in COVID-19 therapy. Currently, no specific therapies against SARS-CoV-2 are available. The MSCs therapy outcomes reported, are striking, as these cells inhibit the over-activation of the immune system, promoting endogenous repair, by improving the lung microenvironment after the SARS-CoV-2 infection. The MSCs could represent an effective, autologous and safe therapy, and therefore, sharing these published results, here is reported the potential use possibilities in COVID-19 of the most common MSCs represented by Adipose Stem Cells (ASCs).
| 83,322 | [
0.1397705078125,
0.07464599609375,
-0.172119140625,
0.5693359375,
-0.5947265625,
0.28515625,
-0.46435546875,
0.59130859375,
0.2073974609375,
0.63134765625,
0.52587890625,
-0.239013671875,
0.560546875,
-0.5078125,
-0.336181640625,
0.387939453125,
-0.2315673828125,
-0.796875,
-0.69... | 33 |
Please summerize the given abstract to a title
Darunavir Ethanolate: Repurposing an Anti-HIV Drug in COVID-19 Treatment
Antivirals already on the market and expertise gained from the SARS and MERS outbreaks are gaining momentum as the most effective way to combat the coronavirus outbreak. SARS-CoV-2 has caused considerable mortality due to respiratory failure, highlighting the immediate need for successful therapies as well as the long-term need for antivirals to combat potential emergent coronaviruses. There are constant viral mutations are being observed due to which world is experiencing different waves of SARS-CoV-2. If our understanding of the virology and clinical presentation of COVID-19 grows, so does the pool of possible pharmacological targets. In COVID-19, the difficulties of proper analysis of current pre-clinical/clinical data as well as the creation of new evidence concerning drug repurposing will be crucial. The current manuscript aims to evaluate the repurposing of an anti-HIV drug Darunavir Ethanolate in COVID-19 treatment with in silico study and we discuss the therapeutic progress of Darunavir Etanolate, to prevent SARS-CoV-2 replication, which supports its clinical assessment for COVID-19 therapy.
| 83,464 | [
0.1109619140625,
-0.2091064453125,
-0.326171875,
0.73388671875,
-0.59716796875,
0.1529541015625,
-0.671875,
0.40087890625,
0.2364501953125,
0.480224609375,
0.123046875,
-0.705078125,
0.1302490234375,
-0.427001953125,
-0.208740234375,
0.302490234375,
-0.22314453125,
-0.58935546875,
... | 33 |
Please summerize the given abstract to a title
A traditional Chinese medicine formula NRICM101 to target COVID-19 through multiple pathways: A bedside-to-bench study
COVID-19 is a global pandemic, with over 50 million confirmed cases and 1.2 million deaths as of November 11, 2020. No therapies or vaccines so far are recommended to treat or prevent the new coronavirus. A novel traditional Chinese medicine formula, Taiwan Chingguan Yihau (NRICM101), has been administered to patients with COVID-19 in Taiwan since April 2020. Its clinical outcomes and pharmacology have been evaluated. Among 33 patients with confirmed COVID-19 admitted in two medical centers, those (n = 12) who were older, sicker, with more co-existing conditions and showing no improvement after 21 days of hospitalization were given NRICM101. They achieved 3 consecutive negative results within a median of 9 days and reported no adverse events. Pharmacological assays demonstrated the effects of the formula in inhibiting the spike protein/ACE2 interaction, 3CL protease activity, viral plaque formation, and production of cytokines interleukin (IL)-6 and tumor necrosis factor (TNF)-α. This bedside-to-bench study suggests that NRICM101 may disrupt disease progression through its antiviral and anti-inflammatory properties, offering promise as a multi-target agent for the prevention and treatment of COVID-19.
| 83,568 | [
-0.2222900390625,
-0.0472412109375,
-0.072509765625,
0.8388671875,
-0.50732421875,
-0.568359375,
0.1710205078125,
0.55419921875,
0.01464080810546875,
0.60400390625,
0.69189453125,
-0.195068359375,
-0.389404296875,
-0.316162109375,
-0.3330078125,
-0.031280517578125,
-0.03973388671875,... | 33 |
Please summerize the given abstract to a title
Role of Homeopathy in Epidemics: Paving Way for a Plausible Solution in the Management of COVID-19/SARS-CoV-2 Infection
The emergence and spread of the novel coronavirus disease 2019 (COVID-19) from Wuhan, China, has become a global threat The high infectivity and drastic outcomes have made this a paramount health concern Effective therapy or vaccine to arrest the progress has still not been proved Homeopathy has a long reputation and evidence of intervening in several epidemic situations, notably the recent influenza Symptoms-based personalised approach makes it more precise to treat patients The symptom complex presented by several patients suffering from the COVID-19 can help to select the genus epidemicus , one or few medicine/s to treat and prevent the epidemic A proper hygienic measure and medication are sufficient to manage a large number of cases with mild symptoms Severe cases with or without complications are an important concern and need critical management A significant body of literature justifies the consideration of homeopathy in this situation A conceptual framework may be drawn to integrate homeopathy with standard therapy to find a better treatment plan Keeping the symptoms and existing evidence in consideration, some medicines may be proposed for further trials, treatment and prevention plan
| 83,906 | [
0.045135498046875,
0.0110015869140625,
-0.0273284912109375,
0.2978515625,
-0.91845703125,
-0.19775390625,
-0.193603515625,
0.463134765625,
0.224609375,
0.537109375,
0.6044921875,
-0.7275390625,
-0.37255859375,
-0.438720703125,
-0.48193359375,
-0.0016307830810546875,
-0.48583984375,
... | 33 |
Please summerize the given abstract to a title
Confronting Covid-19 by exploring the possibility of vaccinating with live SARS-CoV-2 virus itself, via a route that would reduce the incidence of pulmonary complications
This article proposes that one should explore whether the pulmonary complications of Covid-19 can be reduced or avoided by bypassing the airway entry of the SARS-CoV-2 virus. This could possibly be achieved by injecting live SARS-CoV-2 virus intradermal (ID), subcutaneous, intra-muscular (IM) or intra-peritoneal (IP), or by targeting the virus to the digestive tract. The effectiveness and innocuity of using those various routes could be tested very rapidly in animal models, such as Macaques, Hamsters, Ferrets or Cats. The hope is that these experiments will reveal a route of inoculation that can reliably lead to bona-fide infections, resulting in strong immune responses, with both cellular and serological components, but with much less viral replication in the lungs. This would not only hopefully reduce the incidence of pulmonary complications in the infected subjects, but would also probably reduce the amount of virus released by them via aerosols, and thus reduce the vector of contagiosity that is hardest to control, and that probably leads most effectively to viral replication in the lungs. If those experiments in animal models reveal that one or several routes can be used effectively to reduce pulmonary pathology, a clinical trial could be conducted in human volunteers with very low risk profiles. The ID route should probably be considered as a priority, since it could double-up as a skin test to reveal the immune status of the recipients towards the SARS-CoV-2 virus. The course of action proposed here may possibly provide a way of taking a step ahead of the virus, and if it works as hoped, could help to end the need for confinement within a matter of months, if not weeks. © 2020 Joly E.
| 83,964 | [
0.334228515625,
0.128173828125,
-0.10107421875,
0.15234375,
-0.41455078125,
-0.04522705078125,
-0.64697265625,
0.5244140625,
-0.07159423828125,
0.57421875,
0.0662841796875,
-0.5712890625,
0.333984375,
-0.5302734375,
-0.361083984375,
0.29248046875,
-0.1151123046875,
-0.478759765625,... | 33 |
Please summerize the given abstract to a title
Drug Interactions for Patients with Respiratory Diseases Receiving COVID-19 Emerged Treatments
Pandemic of coronavirus disease (COVID-19) is still pressing the healthcare systems worldwide. Thus far, the lack of available COVID-19-targeted treatments has led scientists to look through drug repositioning practices and exploitation of available scientific evidence for potential efficient drugs that may block biological pathways of SARS-CoV-2. Till today, several molecules have emerged as promising pharmacological agents, and more than a few medication protocols are applied during hospitalization. On the other hand, given the criticality of the disease, it is important for healthcare providers, especially those in COVID-19 clinics (i.e., nursing personnel and treating physicians), to recognize potential drug interactions that may lead to adverse drug reactions that may negatively impact the therapeutic outcome. In this review, focusing on patients with respiratory diseases (i.e., asthma or chronic obstructive pulmonary disease) that are treated also for COVID-19, we discuss possible drug interactions, their underlying pharmacological mechanisms, and possible clinical signs that healthcare providers in COVID-19 clinics may need to acknowledge as adverse drug reactions due to drug-drug interactions.
| 83,976 | [
-0.163330078125,
-0.1973876953125,
0.052947998046875,
0.6162109375,
-0.66796875,
-0.447509765625,
-0.259033203125,
0.15087890625,
0.026458740234375,
0.69140625,
0.77734375,
-0.378173828125,
0.0618896484375,
-0.56982421875,
-0.31396484375,
0.4677734375,
-0.439453125,
-0.126708984375... | 33 |
Please summerize the given abstract to a title
Fecal microbiota transplantation for COVID-19; a potential emerging treatment strategy
At the end of 2019, an emerging outbreak caused by Severe Acute Respiratory Syndrome (SARS)-CoV-2 that first reported from Wuhan, China. The first manifestations of patients infected with SARS-CoV-2 was flu-like symptoms, while other type of manifestations, especially gastrointestinal manifestations were discovered recently. As of June 2020, there is no specific drug or treatment strategy for COVID-19, a disease caused by SARS-CoV-2, so different combination of antiviral drugs is currently being used. Gut microbiota mostly consists of four phyla, including Firmicutes, Bacteroidetes, Proteobacteria, and Actinobacteria. The interaction between gut microbiota and immune system through releasing some cytokines such as IL-1β, IL-2, IL-10, TNF-α, and IFN-γ that play roles in the severity of COVID-19. In this article, a new potential treatment for COVID-19 by fecal microbiota transplantation (FMT) is described. FMT revealed promising results in different diseases, especially recurrent clostridium difficile infection, and it might reduce length of hospital admission and severity of the disease by modification of gut microbiota composition.
| 84,089 | [
0.2303466796875,
-0.487548828125,
-0.3583984375,
0.7998046875,
-0.6767578125,
-0.2012939453125,
-0.287353515625,
0.517578125,
0.369140625,
0.71240234375,
0.1785888671875,
-0.642578125,
0.77001953125,
-0.4873046875,
-0.9013671875,
0.24560546875,
-0.281005859375,
-0.51025390625,
-0... | 33 |
Please summerize the given abstract to a title
The british variant of the new coronavirus-19 (Sars-cov-2) should not create a vaccine problem
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a highly contagious virus that infects humans and a number of animal species causing coronavirus disease-19 (COVID-19), a respiratory distress syndrome which has provoked a global pandemic and a serious health crisis in most countries across our planet. COVID-19 inflammation is mediated by interleukin (IL)-1 and is a disease that can cause symptoms such as fever, cough, lung inflammation, thrombosis, stroke, renal failure and headache, to name a few. Strategies that inhibit IL-1 are certainly helpful in COVID-19 and can represent one of the therapeutic options. However, to date, COVID-19 therapy has been scarce and, in many cases, ineffective, since there are no specific drugs other than vaccine that can solve this serious health problem. Messenger RNA (mRNA) vaccines, which are the newest approach, are already available and will certainly meet the many expectations of the population. mRNA vaccines, coated with protected soft fatty lipids, use genetic mRNA (plus various inactive excipients) to make a piece of the coronavirus spike protein, which will instruct the immune system to produce specific antibodies. The soft fatty lipids allow the entry of mRNA into cells where it is absorbed into the cytoplasm and initiates the synthesis of the spike protein. In addition, vaccination also activates T cells that help the immune system respond to further exposure to the coronavirus. mRNA induces the synthesis of antigens of SARS-CoV-2 virus which stimulates the antibody response of the vaccinated person with the production of neutralizing antibodies. The new variant of the coronavirus-19 has been detected in the UK where, at present, the government has imposed a lockdown with restrictions on international movements. The virus variant had already infected 1/4 of the total cases and in December 2020, it reached 2/3 of those infected in the UK. It has been noted that the spreading rate of the British variant could be greater than 70% of cases compared to the normal SARS-CoV-2 virus, with an R index growth of 0.4. Recent studies suggest.
| 84,098 | [
0.240234375,
0.305908203125,
0.37451171875,
0.77294921875,
-0.69091796875,
-0.44140625,
-0.1375732421875,
0.51953125,
-0.36083984375,
0.103759765625,
-0.056304931640625,
-0.2252197265625,
0.10009765625,
-0.404052734375,
-0.57470703125,
-0.1837158203125,
-0.2332763671875,
-0.8037109... | 33 |
Please summerize the given abstract to a title
Bovine Serum Albumin-Coated Niclosamide-Zein Nanoparticles as Potential Injectable Medicine against COVID-19
(1) Background: COVID-19 has affected millions of people worldwide, but countries with high experimental anti-SARS-CoV-2 vaccination rates among the general population respectively show progress in achieving general herd immunity in the population (a combination of natural and vaccine-induced acquired immunity), resulting in a significant reduction in both newly detected infections and mortality rates. However, the longevity of the vaccines’ ability to provide protection against the ongoing pandemic is still unclear. Therefore, it is of utmost importance to have new medications to fight against the pandemic at the earliest point possible. Recently, it has been found that repurposing already existing drugs could, in fact, be an ideal strategy to formulate effective medication for COVID-19. Though there are many FDA-approved drugs, it has been found that niclosamide (NIC), an anthelmintic drug, has significantly high potential against the SARS-CoV-2 virus. (2) Methods: Here we deployed a simple self-assembling technique through which Zein nanoparticles were successfully used to encapsulate NIC, which was then coated with bovine serum albumin (BSA) in order to improve the drugs’ stability, injectablity, and selectivity towards the virus-infected cells. (3) Results: The particle size for the BSA-stabilized Zein-NIC nanohybrid was found to be less than 200 nm, with excellent colloidal stability and sustained drug release properties. In addition, the nanohybrid showed enhanced drug release behavior under serum conditions, indicating that such a hybrid drug delivery system could be highly beneficial for treating COVID-19 patients suffering from high endothelial glycocalyx damage followed by a cytokine storm related to the severe inflammations.
| 84,150 | [
-0.1446533203125,
-0.327392578125,
0.0716552734375,
0.7314453125,
-0.56982421875,
-0.0207977294921875,
-0.0206451416015625,
0.15576171875,
0.325927734375,
0.451416015625,
0.2327880859375,
-0.53564453125,
0.345703125,
-0.31396484375,
-0.8369140625,
0.92333984375,
-0.4287109375,
-0.8... | 33 |
Please summerize the given abstract to a title
Role of different types of nanomaterials against diagnosis, prevention and therapy of COVID-19
In 2019, a novel type of coronavirus emerged in China called SARS-COV-2, known COVID-19, threatens global health and possesses negative impact on people's quality of life, leading to an urgent need for its diagnosis and remedy. On the other hand, the presence of hazardous infectious waste led to the increase of the risk of transmitting the virus by individuals and by hospitals during the COVID-19 pandemic. Hence, in this review, we survey previous researches on nanomaterials that can be effective for guiding strategies to deal with the current COVID-19 pandemic and also decrease the hazardous infectious waste in the environment. We highlight the contribution of nanomaterials that possess potential to therapy, prevention, detect targeted virus proteins and also can be useful for large population screening, for the development of environmental sensors and filters. Besides, we investigate the possibilities of employing the nanomaterials in antiviral research and treatment development, examining the role of nanomaterials in antiviral- drug design, including the importance of nanomaterials in drug delivery and vaccination, and for the production of medical equipment. Nanomaterials-based technologies not only contribute to the ongoing SARS- CoV-2 research efforts but can also provide platforms and tools for the understanding, protection, detection and treatment of future viral diseases.
| 84,169 | [
0.172119140625,
-0.242919921875,
0.01224517822265625,
0.544921875,
-0.73046875,
-0.2401123046875,
-0.56689453125,
0.312255859375,
0.2261962890625,
0.40087890625,
0.499267578125,
-0.6435546875,
0.36083984375,
-0.8349609375,
-0.67138671875,
0.11883544921875,
-0.443115234375,
-0.75830... | 33 |
Please summerize the given abstract to a title
Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19
Since the outbreak of coronavirus disease (COVID-19) that was discovered in 2019 in Wuhan, China, no standard therapy guideline has been set despite the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its high infectivity. The globally pandemic outbreak suggests that COVID-19 was highly infectious and difficult to control. A dual-combination of ribavirin and interferon-α has been the widely used regimen for the treatment of this disease in China. However, due to the varying results of treatment with these drugs, a novel antiviral combination therapy is urgently needed. This case reports the usage of lopinavir/ritonavir-based combination antiviral regimen for a patient with SARS-CoV-2 infection.
| 84,343 | [
0.08111572265625,
-0.344970703125,
0.07061767578125,
0.259521484375,
-0.9716796875,
-0.1734619140625,
-0.433837890625,
0.490234375,
0.3701171875,
0.56689453125,
0.61865234375,
-0.297607421875,
-0.34619140625,
-0.364990234375,
-0.5146484375,
0.465087890625,
-0.93212890625,
-0.626953... | 33 |
Please summerize the given abstract to a title
Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2
Abstract Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in Wuhan, China, and has subsequently spread worldwide. In the absence of any antiviral or immunomodulatory therapies, the disease is spreading at an alarming rate. A possibility of a resurgence of COVID-19 in places where lockdowns have already worked is also developing. Thus, for controlling COVID-19, vaccines may be a better option than drugs. An mRNA-based anti-COVID-19 candidate vaccine has entered a phase 1 clinical trial. However, its efficacy and potency have to be evaluated and validated. Since vaccines have high failure rates, as an alternative, we are presenting a new, designed multi-peptide subunit-based epitope vaccine against COVID-19. The recombinant vaccine construct comprises an adjuvant, cytotoxic T-lymphocyte (CTL), helper T-lymphocyte (HTL), and B-cell epitopes joined by linkers. The computational data suggest that the vaccine is non-toxic, non-allergenic, thermostable, with the capability to elicit a humoral and cell-mediated immune response. The stabilization of the vaccine construct is validated with molecular dynamics simulation studies. This unique vaccine is made up of 33 highly antigenic epitopes from three proteins that have a prominent role in host-receptor recognition, viral entry, and pathogenicity. We advocate this vaccine must be synthesized and tested urgently as a public health priority.
| 84,371 | [
-0.07257080078125,
-0.1392822265625,
-0.288818359375,
0.297119140625,
-0.47412109375,
-0.2269287109375,
-0.7373046875,
0.410888671875,
0.13623046875,
0.417724609375,
0.241943359375,
-0.5810546875,
-0.117919921875,
-0.275146484375,
-0.454345703125,
0.1143798828125,
-0.279541015625,
... | 33 |
Please summerize the given abstract to a title
COVID19db: a comprehensive database platform to discover potential drugs and targets of COVID-19 at whole transcriptomic scale
Many open access transcriptomic data of coronavirus disease 2019 (COVID-19) were generated, they have great heterogeneity and are difficult to analyze. To utilize these invaluable data for better understanding of COVID-19, additional software should be developed. Especially for researchers without bioinformatic skills, a user-friendly platform is mandatory. We developed the COVID19db platform (http://hpcc.siat.ac.cn/covid19db & http://www.biomedical-web.com/covid19db) that provides 39 930 drug–target–pathway interactions and 95 COVID-19 related datasets, which include transcriptomes of 4127 human samples across 13 body sites associated with the exposure of 33 microbes and 33 drugs/agents. To facilitate data application, each dataset was standardized and annotated with rich clinical information. The platform further provides 14 different analytical applications to analyze various mechanisms underlying COVID-19. Moreover, the 14 applications enable researchers to customize grouping and setting for different analyses and allow them to perform analyses using their own data. Furthermore, a Drug Discovery tool is designed to identify potential drugs and targets at whole transcriptomic scale. For proof of concept, we used COVID19db and identified multiple potential drugs and targets for COVID-19. In summary, COVID19db provides user-friendly web interfaces to freely analyze, download data, and submit new data for further integration, it can accelerate the identification of effective strategies against COVID-19.
| 84,419 | [
-0.224609375,
-0.3212890625,
-0.058563232421875,
0.470458984375,
-0.35302734375,
0.051727294921875,
-0.21044921875,
0.515625,
0.2763671875,
0.313720703125,
0.31494140625,
-0.77685546875,
-0.045166015625,
-0.576171875,
0.083740234375,
0.6513671875,
-0.431640625,
-0.45458984375,
0.... | 33 |
Please summerize the given abstract to a title
Identification of potential pan-coronavirus therapies using a computational drug repurposing platform
In the past 20 years, there have been several infectious disease outbreaks in humans for which the causative agent has been a zoonotic coronavirus. Novel infectious disease outbreaks, as illustrated by the current coronavirus disease 2019 (COVID-19) pandemic, demand a rapid response in terms of identifying effective treatments for seriously ill patients. The repurposing of approved drugs from other therapeutic areas is one of the most practical routes through which to approach this. Here, we present a systematic network-based drug repurposing methodology, which interrogates virus–human, human protein–protein and drug–protein interactome data. We identified 196 approved drugs that are appropriate for repurposing against COVID-19 and 102 approved drugs against a related coronavirus, severe acute respiratory syndrome (SARS-CoV). We constructed a protein–protein interaction (PPI) network based on disease signatures from COVID-19 and SARS multi-omics datasets. Analysis of this PPI network uncovered key pathways. Of the 196 drugs predicted to target COVID-19 related pathways, 44 (hypergeometric p-value: 1.98e-04) are already in COVID-19 clinical trials, demonstrating the validity of our approach. Using an artificial neural network, we provide information on the mechanism of action and therapeutic value for each of the identified drugs, to facilitate their rapid repurposing into clinical trials.
| 84,423 | [
0.11541748046875,
0.007450103759765625,
-0.2025146484375,
0.5869140625,
-0.7724609375,
-0.2685546875,
-0.62060546875,
-0.007720947265625,
0.127197265625,
0.55126953125,
0.36279296875,
-0.57470703125,
-0.1649169921875,
-0.65625,
-0.39013671875,
0.45458984375,
-0.64306640625,
-0.2729... | 33 |
Please summerize the given abstract to a title
Quality Assessment of the Clinical Trial Protocols Regarding Treatments for Coronavirus Disease 2019
Background: With the global spread of coronavirus disease 2019 (COVID-19), an increasing number of clinical trials are being designed and executed to evaluate t
| 84,426 | [
0.06842041015625,
-0.34033203125,
-0.23681640625,
0.77880859375,
-0.826171875,
-0.4755859375,
-0.0657958984375,
0.63916015625,
0.412109375,
0.7041015625,
0.343017578125,
0.328125,
-0.21728515625,
-0.4716796875,
-0.302001953125,
0.59814453125,
-0.426025390625,
-0.8916015625,
-0.04... | 33 |
Please summerize the given abstract to a title
The Role of Type III Interferons in Human Disease.
PURPOSE This literature review summarizes the main immunological characteristics of type III interferons (IFN) and highlights the clinically relevant aspects and future therapeutic perspectives for these inflammatory molecules. SOURCE Relevant articles in PubMed MEDLINE from the first publication (2003) until 2020. N=101 articles were included in this review. PRINCIPAL FINDINGS Type III IFNs represent a relatively newly described inflammatory cytokine family. Although they induce substantially similar signalling to the well-known type I IFNs, significant functional differences make these molecules remarkable. Type III IFNs have extensive biological effects, contributing to the pathogenesis of several diseases and also offering new diagnostic and therapeutic approaches: 1) their potent anti-viral properties make them promising therapeutics against viral hepatitis and even against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is causing the current coronavirus disease 2019 (COVID-19) pandemic; 2) imbalances in the IFN-λs contribute to several forms of chronic inflammation (e.g., systemic and organ-specific autoimmune diseases) and potentially predict disease progression and therapeutic response to biologic therapies; and 3) the antitumor properties of the type III IFNs open up new therapeutic perspectives against malignant diseases. CONCLUSION Over the last 18 years, researchers have gathered extensive information about the presence and role of these versatile inflammatory cytokines in human diseases, but further research is needed to clarify the mechanistic background of those observations. Better understanding of their biological activities will permit us to use type III IFNs more efficiently in new diagnostic approaches and individualized therapies, consequently improving patient care.
| 84,522 | [
0.04620361328125,
-0.036956787109375,
-0.0645751953125,
0.416015625,
-0.787109375,
0.31201171875,
-0.6591796875,
0.349609375,
0.005344390869140625,
0.677734375,
0.1993408203125,
-0.27783203125,
-0.00047206878662109375,
-0.1678466796875,
-0.54052734375,
-0.489501953125,
-0.26196289062... | 33 |
Please summerize the given abstract to a title
Pausing the Fight Against Malaria to Combat the COVID-19 Pandemic in Africa: Is the Future of Malaria Bleak?
Malaria remains a major global health burden, killing hundreds of thousands annually, especially in sub-Saharan Africa. In 2019, a Phase IV Expanded Programme on Immunization (EPI)-linked malaria vaccine implementation was underway. However, in December 2019, a novel pneumonia condition termed coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with many clinical, epidemiological, and biological parallels to malaria, was reported in Wuhan, China. COVID-19 is spreading rapidly, and, as of the 3rd of June, 2020, more than 382,507 persons had died from COVID-19. Children under 5 years who suffer high malaria-attributable mortalities are largely asymptomatic for COVID-19. Considering that the malaria burden is highest in low-income tropical countries with little capacity to fund malaria control and eradication programs, the fight against malaria in these regions is likely to be hampered. Access to healthcare has generally been limited, while malaria interventions, such as seasonal malaria chemotherapy and distribution of insecticide-treated bed nets, have been suspended due to lockdowns. Likewise, the repurposing of antimalarials for treatment of COVID-19 shared symptoms and the shift in focus from the production of malaria rapid diagnostic tests (RDTs) to COVID-19 RDTs is a cause for concern in malaria-endemic regions. Children are less affected by the COVID-19 pandemic compared to the elderly. However, due to the fears of contracting SARS-CoV-2, the elderly who are worst affected by COVID-19 may not take children for malaria medication, resulting in high malaria-related mortalities among children. COVID-19 has disproportionately affected developed countries, threatening their donation capacity. These are likely to thwart malaria control efforts in low-income regions. Here, we present perspectives on the collateral impact of COVID-19 on malaria, especially in Africa.
| 84,668 | [
0.0665283203125,
-0.051300048828125,
-0.5498046875,
0.50732421875,
-0.396728515625,
-0.11761474609375,
-0.425048828125,
0.256103515625,
0.290283203125,
0.5263671875,
0.0911865234375,
-0.54833984375,
-0.205078125,
-0.483154296875,
-0.1903076171875,
0.04705810546875,
-0.548828125,
-0... | 33 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.